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ABSTRACT
Invasive infections caused by Streptococcus pyogenes, also known as Group A
Strep (GAS), results in approximately 600,000 deaths annually. With evidence of
antibiotic-resistant strains of this bacterium on the rise, there is a need for the identification
of new drug targets to control these infections. In our approach we target the quinolinatesalvage pathway (QSP) and the streptolysin S (SLS) biosynthesis pathway. The QSP
provides a secondary pathway for NAD+ biosynthesis within this organism; the SLS
pathway leads to the formation of a quorum sensing molecule (SLS). We hypothesize that
inhibition of the pathways will lead to GAS cell death or will impair the growth of the
bacterium.
This dissertation presents results of the functional and structural (using x-ray
crystallography) characterization of select proteins involved in these pathways. Highlights
of the information contained within each chapter are as follows:


Chapter 1 provides background information on the QSP and SLS pathways and
reports current research on both targets.



Chapter 2 describes results from structural studies on quinolinate
phosphoribosyltransferase (spNadC), of the QSP, and shows results from
functional and structural studies, as well as the first structures of this protein
and its deletion mutant (spNadC69A).



Chapter 3 reports the results from functional characterization of nicotinate
mononucleotide adenyltransferase (spNadD) of the QSP. Preliminary
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structural studies are described. While the protein structure was not yet
determined, homology modeling was used to provide insights into the proposed
spNadD structure.


Chapter 4 details the functional and structural studies on NAD+ synthetase
(spNadE) of the QSP. This protein, similarly to NadD, is considered to be a
good drug target. This chapter describes the first structures of this protein
determined in GAS. Structural results provide new details for the reaction
mechanism and the conversion of the substrate (nicotinate adenine dinucleotide
(NaAD)) into nicotinamide adenine dinucleotide (NAD+) through channels
identified at the dimer interface of spNadE.



Chapter 5 describes results from molecular cloning, isolation, and refolding
experiments conducted on select SLS biosynthesis proteins: SagB, SagC,
SagD, and SagG. Structures of these proteins have not been determined;
however, molecular cloning experiments for the co-expression of the SagBCD
complex have shown promising results.
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CHAPTER 1
INTRODUCTION TO STREPTOCOCCUS PYOGENES AND THE BIOSYNTHESIS OF NICOTINAMIDE
ADENINE DINUCLEOTIDE AND STEPTOLYSIN S
1.1 BACKGROUND AND INTRODUCTION TO STREPTOCOCCUS PYOGENES
Streptococcus pyogenes, also known as Group A Streptococcus (GAS), is a
virulent, β-hemolytic, bacterium (1). It is a gram positive, anaerobic, spore-forming
bacterium that requires nutrient rich environments for optimal growth. This fact makes the
human body an ideal host for this organism (2). GAS is responsible for the onset of
infections associated with acute pharyngitis (strep throat), rheumatic fever, scarlet fever,
toxic shock syndrome, and necrotizing fasciitis (2, 3).
1.2 GLOBAL IMPACT
Globally, severe cases of GAS diseases cause over 500,000 deaths per year, which
places GAS among the ten most common causes of death due to human pathogens (4). In
less developed countries, specifically Papua New Guinea, Ethiopia, Gambia, and the
Philippines, invasive GAS infections attribute to approximately 663,000 new cases a year.
An estimated 160,000 deaths of children, 90 days and younger, make up one third of the
fatalities (4). In children 15 years and younger, 25% of GAS infections are considered fatal
and a higher percentage is assumed in undocumented, lesser developed communities (4).
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The CDC reports that penicillin is still an effective antibiotic for treatment of GAS
infection, but macrolide, tetracycline, and clindamycin-resistant strains have been
identified (5). As a result of these findings, new antibiotics must be created to treat these
resistant strains. This dissertation will explain two new strategies for antibiotic
development through the use of macromolecular structure-based drug design.
1.3 THE QUINOLINATE-SALVAGE PATHWAY AND NAD+ BIOSYNTHESIS
Previous studies have identified that non-specific exotoxin release from GAS
during infection promotes the activation of interferon-gamma (IFN-) (6). IFN- aids in the
initiation of tryptophan degradation by monocytes (blood)/macrophages (tissue) by way of
the kynurenine pathway (6, 7). The end products of this pathway are quinolinic acid (QA)
and picolinic acid (8). It could be presumed that there would be increased levels of
tryptophan degradation and consequently, high levels of quinolinate at the site of infection
due to immune response.
GAS has evolved to utilize quinolinate, by the action of the quinolinate-salvage
pathway (QSP) (1). This ability affords these bacterial species the capacity to use this
molecule for essential biochemical processes where similar streptococcal species could
not. Moreover, this adaptation improves GAS's odds of survival and could promote an
increased virulence when compared to other opportunistic bacteria. Previous studies have
identified that this pathway is responsible for the utilization of quinolinic acid for the
biosynthesis of nicotinamide adenine dinucleotide (NAD+) (1). NAD+ is a necessary
cofactor in the progression of numerous biochemical pathways including glycolysis,
gluconeogenesis, the citric acid cycle, and the electron transport chain (9). The QSP is
composed of quinolinate-salvage enzymes (QSEs): quinolinate phosphoribosyltansferase
2

(spNadC), nicotinate mononucleotide transferase (spNadD), and NAD synthetase
(spNadE), which are collectively responsible for the conversion of quinolinate (QA),
nicotinate/ niacin (Na), and nicotinamide (Nm) into NAD+ (Figure 1.1) (1). Specifically,
for the utilization of QA, NadC is responsible for the conversion of phosphoribosyl
pyrophosphate (PRPP) and QA into nicotinate mononucleotide (NaMN) (1).

This

transformation is regarded as the first of three biosynthetic steps in the formation of NAD+
(1). The two remaining biosynthetic steps are completed by the action of NadD and NadE
(1). NadD is responsible for the conversion of NaMN and Adenosine triphosphate (ATP)
into nicotinic acid adenine dinucleotide (NaAD) and NadE is responsible for the transfer
of ammonia to convert NaAD into NAD+ (1, 10). Detailed explanations of QSE activity
will be explained in their respective chapters. Figure 1.2 provides an overview of the
reactions catalyzed by the activity of the QSEs.
1.4 VIRULENCE AND STREPTOLYSIN S BIOSYNTHESIS
GAS comes in a number of different forms known as serotypes (11). These
serotypes (M1-6, M12, M18, M28, M49) are all descriptions of minor genetic variations
between different strains of GAS (11). The M designation comes from a product of the
bacteria’s emm gene referred to as the “M-protein” (11). This protein is a major factor in
the classification and determination of the virulence of GAS strains. Other factors include
streptococcal phospholipase (Sla), which is responsible for promoting adherence of GAS
to epithelial tissue, streptococcal chemokine protease (SpyCEP), which promotes the
destruction of interleukin signaling proteins, and immunoglobulin G degrading enzyme
(Mac1), which is considered to be responsible for antibody degradation (11, 12).
Furthermore, additional components are streptococcal inhibitor of complement (Sic) and
3

complement 5A peptidase (ScpA), both of which inhibit the activity of the complement
system, and streptolysin O and S (SLO and SLS) which utilize different mechanisms for
the lysis of different cell types (11).
SLS can promote the lysis of red and white blood cells, platelets, and subcellular
organelles (2, 11). As a result, GAS gains access to nutrients and evades the body’s
immune defenses (11). Supplemented by the activity of the virulence proteins described
above, the immune system manifests the site of infection as a location that looks as if skin
has been eaten away (11). This description triggered the “flesh-eating bacteria” moniker,
which is commonly used to describe GAS-related necrotizing fasciitis.
1.5 RELEVANCE AND HYPOTHESES
Severe GAS infections, like necrotizing fasciitis, are serious disorders and if left
untreated can result in gruesome and disfiguring maladies. Severe infections can lead to
amputations and even death. The general focus of this research resides in understanding
the means by which GAS promotes infection and contributes to onset of necrotizing
fasciitis. We presume that the inhibition of SLS and NAD+ biosynthesis can be
accomplished in order to prevent the progression of infection.
More specifically, focus of this is work is two-fold:
1. We are interested in the isolation and structural determination of the proteins
involved in the activity of the QSP for structure-based inhibitor design. We
hypothesize that through the inhibition of the QSEs, we can stop bacterial growth.
2. We are interested in the isolation and structural determination of the proteins
involved in the biosynthesis and release of Streptolysin S. We hypothesize that
through the inhibition of proteins involved in the biosynthesis of SLS (SagB-D)
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and its release (SagG) we can prevent SLS formation, and/or stop the progression
of necrotizing fasciitis.
1.6 CURRENT RESEARCH INTO THE QSP AND NAD+ BIOSYNTHESIS
According to Sorci et al., the QSP operates as a secondary pathway in the formation
of NAD+ (1). The capacity to express spNadC is the key factor in this process. Genomic
studies of streptococcal species revealed that nadC is present only in Streptococcus
pyogenes and Streptococcus pneumoniae and may be related to the increased virulence as
compared to other, less invasive, streptococci (1).
In opportunistic streptococcal species, e.g. Streptococcus mutants and
Streptococcus agalactiae, the process of NAD+ biosynthesis starts at the introduction of
Na and Nm by the action of the NiaX membrane transporter. NiaX has been previously
identified as a Na transporter which allows for the transport of Na and Nm across the cell
membrane into the cytoplasm (1). The next biosynthetic step is the conversion of Na into
NaMN by the action of nicotinate phosphoribosyl transferase (PncB) (1). Prior to the
conversion to NamN, Nm must be converted to Na before NaMN biosynthesis can occur
(1). The conversion is completed by the action of PncA nicotidaminase (PncA) which
substitutes a hydroxyl group for an amine group before conversion to NaMN by PncB (1).
As described above, other opportunistic bacteria also encode for NadD which converts
NaMN into NaAD, and NadE which converts NaAD into NAD+ (1). Refer to Figure 1.8.1
for a general schematic of this process.
Avirulent streptococci, e.g. Streptococcus equi and Streptococcus suis, utilize a
more simplified approach to NAD+ biosynthesis (1). After the transport of nicotinamide
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riboside (NmR) into the cell by PnuC (an NmR transporter), NadR biochemically modifies
NmR by operating as a dual-action enzyme. Its first action is to operate as a nucleoside
kinase converting NmR to nicotinamide mononucleotide (NMN); the second action is as
an adenyltransferase converting NMN to NAD+ (13). Figure 1.1 also provides a general
description of this process.
What separates GAS and S. pneumonia from the other streptococcal species is their
ability to utilize a third pathway in combination with the pathway used by opportunistic
species, described above (1). Both species encode for a NadC and convert QA, which is
produced during infection, into NaMN for use by NadD, and eventually NadE, for the
formation of NAD+ (1). Original speculation was that QA was produced internally by the
bacteria through aspartate metabolism by L-aspartate oxidase (NadB), and iminoaspartate
metabolism by quinolinic acid synthetase (NadA) was proposed to lead to formation of QA
as an end-product (1). It was concluded from knockout studies of PncA and NadC that
NadC is obtained from the extracellular environment (1). A simplified description of this
process can also be found in Figure 1.1.
In knockout studies of NadD and NadE homologs in Mycobacterium species, it was
discovered that NadD and NadE were essential for the survival of the species, and their
loss diminished NAD+ biosynthesis intermediate production and lead to cell death (14)
In this dissertation, the first published structures of NadC and NadE will be
presented. To date, there is currently no structural data on any of the QSE's from S.
pyogenes.
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1.7 CURRENT RESEARCH INTO STREPTOLYSIN S (SLS) BIOSYNTHESIS
SLS is a bacteriocin, which is synthesized from the collective activity of the
streptolysin associated gene operon (sag operon) of the S. pyogenes genome (2, 15). The
sag operon is a collective of nine open reading frames (ORF's) referred to as sagA – sagI
(15). All the ORFs encode for proteins necessary for the biosynthesis and export of SLS
(2). The sagA gene encodes for a 53 amino acid strand (SagA) that acts as a precursor for
the formation of SLS (2, 15); upon modification by operon proteins, it forms mature SLS
(2, 16). SagB is proposed to act as a dehydrogenase working in conjunction with SagC and
SagD, which allows for the withdrawal of necessary hydrogens in preparation for mature
SLS formation (16). SagC is suggested to operate as a cyclodehydratase that plays a role
in the conversion of cysteine, serine, and threonine residues of immature SLS into oxazole,
thiazole, and methyloxazole, respectively, to form mature SLS (16). SagD is proposed to
be responsible for the formation of the SagBCD complex and functions in the regulation
of the complex’s activity (16). SagE has been reported to have two roles: to act as a
peptidase to promote the removal of an inactive peptide strand of SagA (approximately 23
amino acids), and to maintain an immunity role in GAS (2). SagG is proposed to act as a
membrane-associated protein responsible for the binding of ATP (2). SagH and SagI work
in conjunction with SagG, and are considered to be responsible for the release of mature
SLS into its extracellular environment (2). SagF is believed to be a membrane-associated
protein, but its function has yet to be defined (2). Figure 1.3 and Table 1.1 provides a
schematic of the activity of the sag operon, as well as a description of the proposed function
of each of the proteins involved.
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At the inception of this project in 2012, the Protein Data Bank (PDB) contained no
other homologous structures with significant sequence similarity, to SagB, SagC, SagD, or
SagG, over the entire sequence (Table 1.2). This observation indicates the possibility of
identifying a new enzyme, which could lead to new opportunities for future studies.
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1.8 FIGURES AND TABLES
Table 1.1: The Sag proteins. This table shows proteins encoded by the sag operon, their
molecular weights, and their proposed function (2).
Protein

# of
Amino
Acids

Molecular Weight
(kDa)

Proposed Function

SagA

53

5

Amino acid precursor of Streptolysin S

SagB

316

36

Dehydrogenase

SagC

352

40

Cyclogenase

SagD
SagE

452
220

51
25

Linker of SagBC?
Immunity role/ Truncation of SagA?

SagF
SagG

227
307

26
41

Membrane associated protein?
ATP Binding Cassette transporter
(ABC transporter)

SagH

375

42

ABC transporter

SagI

372

41

ABC transporter
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Table 1.2: Sag proteins and their homologs in PDB. These are results of a sequence based
search for proteins similar to SagB, SagC, SagD, and SagG with structures reported to
Protein Data Bank. The results show very low sequence similarity of SagB-G to proteins
with known structures (19).
Protein

SagB

SagC

# of
amino
acids

The most similar protein
with known structure as
identified with BLAST

Sequence
identity (%)

316

Thermotoga maritima,
bacterioferritin
comigratory protein

18

Length of the
similar protein
fragment
(# amino acids)
57

10

35

23

103

41

125

352

PDB code: 4EO3
Escherichia coli MccB
protein
PDB code: 3H9G

SagD

452

SagG

307

Prochloron sp. 06037A
heterocyclase TruD
PDB code: 4BS9
Thermotoga maritima
Abc Transporter Atp-binding
Protein

PDB code: 4YER
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Figure 1.1: Integrated pathway for NAD+ biosynthesis in streptococcal species. This
schematic diagram, adapted from Sorci et al., displays proteins and intermediates involved
in NAD+ biosynthesis in all Streptococcal species (1). Virulent species of Streptococci,
specifically S. pneumoniae and S. pyogenes, exhibit the ability to utilize quinolinate as an
alternate route for nicotinate mononucleotide (NaMN) production which may provide an
explanation for the increased virulence of these species (1).

11

Figure 1.2: The quinolinate-salvage pathway. This figure displays a general description of
the enzymatic activities of the proteins of the QSP (1).
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Figure 1.3: The sag operon. This figure, adapted from Molloy et al., provides an overview
of the proposed activity of the sag operon during infection. SagA is converted into SLS by
the collective activity of the the SagBCD complex and SagE (2, 16). SagGHI work together
to form the proposed ATP binding cassette responsible for the transfer of SLS from the
intracellular environment to the extracellular environment (2). Once SLS exits the cell it
can cause the destruction of red blood cells, white blood cells, and platelets. SagF is labeled
with a question mark because the function of the protein has yet to be defined. (2)

13

1.9 REFERENCES:
1. Sorci, L., I. K. Blaby, I. A. Rodionova, J. De Ingeniis, S. Tkachenko, V. De CrecyLagard, and A. L. Osterman. "Quinolinate Salvage and Insights for Targeting NAD
Biosynthesis in Group A Streptococci." Journal of Bacteriology 195.4 (2012): 726-32.
Web.
2. Molloy, Evelyn M., Paul D. Cotter, Colin Hill, Douglas A. Mitchell, and R. Paul Ross.
"Streptolysin S-like Virulence Factors: The Continuing SagA." Nature Reviews
Microbiology Nat Rev Micro 9.9 (2011): 670-81. Web.
3. Bauman, Robert W., Elizabeth Machunis-Masuoka, and Ian R. Tizard. Microbiology.
San Francisco:Pearson/Benjamin Cummings, 2004.
4. Carapetis, Jonathan R., Andrew C. Steer, E. Kim Mulholland, and Martin Weber. "The
Global Burden of Group A Streptococcal Diseases." The Lancet Infectious
Diseases 5.11 (2005): 685-94. Web.
5. Rubio-López, Virginia, Sylvia Valdezate, David Álvarez, Pilar Villalón, María
Medina, Celia Salcedo, and Juan-Antonio Sáez-Nieto. "Molecular Epidemiology,
Antimicrobial Susceptibilities and Resistance Mechanisms of Streptococcus Pyogenes
Isolates Resistant to Erythromycin and Tetracycline in Spain (1994–2006)."BMC
Microbiology BMC Microbiol 12.1 (2012): 215. Web.
6. Murr, Christian, Dieter Gerlach, Bernhard Widner, Manfred P. Dierich, and Dietmar
Fuchs. "Neopterin Production and Tryptophan Degradation in Humans Infected by
Streptococcus Pyogenes." Medical Microbiology and Immunology 189.3 (2001): 16163. Web.
7. Heyes, M. P., K. Saito, and S. P. Markey. "Human Macrophages Convert L-tryptophan
into the Neurotoxin Quinolinic Acid." Biochem. J. Biochemical Journal 283.3 (1992):
633-35. Web.
8. Grant, R. S., S. E. Coggan, and G. A. Smythe. "The Physiological Action of Picolinic
Acid in the Human Brain." International Journal of Tryptophan Research 2 (2009):
71-79. Web
9. Voet, Donald, and Judith G. Voet. Biochemistry. 4th ed. Hoboken, NJ: Wiley, 2011.
Print. pgs 585-823
10. Cao, Hong, Beth L. Pietrak, and Charles Grubmeyer. "Quinolinate
Phosphoribosyltransferase: Kinetic Mechanism for a Type II PRTase
†." Biochemistry 41.10 (2002): 3520-528. Web.
11. Olsen, Randall J., and James M. Musser. "Molecular Pathogenesis of Necrotizing
Fasciitis." Annual Review of Pathology: Mechanisms of Disease 5.1 (2010): 1-31.
Print.
12. Zingaretti, C., F. Falugi, V. Nardi-Dei, G. Pietrocola, M. Mariani, S. Liberatori, M.
Gallotta, M. Tontini, C. Tani, P. Speziale, G. Grandi, and I. Margarit. "Streptococcus
Pyogenes SpyCEP: A Chemokine-inactivating Protease with Unique Structural and
Biochemical Features." The FASEB Journal 24.8 (2010): 2839-848. Print
13. Grose, J. H., U. Bergthorsson, and J. R. Roth. "Regulation of NAD Synthesis by the
Trifunctional NadR Protein of Salmonella Enterica." Journal of Bacteriology 187.8
(2005): 2774-782. Web.
14. Rodionova, I. A., B. M. Schuster, K. M. Guinn, L. Sorci, D. A. Scott, X. Li, I.
Kheterpal, C. Shoen, M. Cynamon, C. Locher, E. J. Rubin, and A. L. Osterman.
14

"Metabolic and Bactericidal Effects of Targeted Suppression of NadD and NadE
Enzymes in Mycobacteria." MBio 5.1 (2014): n. pag. Web.
15. Nizet, V., B. Beall, D. J. Bast, V. Datta, L. Kilburn, D. E. Low, and J. C. S. De Azavedo.
"Genetic Locus for Streptolysin S Production by Group A Streptococcus." Infection
and Immunity 68.7 (2000): 4245-254. Web.
16. Mitchell, Douglas A., Shaun W. Lee, Morgan A. Pence, Andrew L. Markley, Joyce
D. Limm, and Victor Nizet. "Structural and Functional Dissection of the Heterocyclic
Peptide Cytotoxin Streptolysin S." Journal of Biolgical Chemistry 284.119 (2009):
13004-3012. Print.
17. Cserzo, M., E. Wallin, I. Simon, G. Von Heijne, and A. Elofsson. "Prediction of
Transmembrane Alpha-helices in Procariotic Membrane Proteins: The Dense
Alignment Surface Method." Protein Engineering 10.6 (1997): 673-76. Print.
18. Hirokawa, T., S. Boon-Chieng, and S. Mitaku. "SOSUI: Classification and Secondary
Structure Prediction System for Membrane Proteins." Bioinformatics 14.4 (1998):
378-79. Print.
19. Magrane, M., and Uniprot Consortium. "UniProt Knowledgebase: A Hub of
Integrated Protein Data." Database 2011 (2011): 2-13. Print.

15

CHAPTER 2
STRUCTURAL AND FUNCTIONAL STUDIES OF QUINOLINATE PHOSPHORIBOSYLTRANSFERASE
FROM STREPTOCOCCUS PYOGENES

2.1 INTRODUCTION
Quinolinate phosphoribosyltransferase (spNadC) is responsible for the first
biosynthetic step in a triad of steps related to the formation of NAD+, by way of the QSP,
in GAS (1). This enzyme is specifically responsible for the N-nucleoside bond formation
between PRPP and QA in order to form NaMN (2). This ability to use QA to biosynthesize
NAD+ enables GAS to use more than one biosynthetic route for NAD+ production.
Therefore, spNadC is also not considered a drug target, since GAS can also use NiaX
membrane proteins in order to utilize nicotinate and nicotinamide for NaMN biosynthesis
(1). The ability to utilize various pathways for NAD+ biosynthesis most likely improves
survival of GAS during infection (1). The purpose of this work is to understand the effect
of spNadC and its role in promoting virulence in GAS.
The genomic studies presented by Sorci et al. indicated that GAS and Streptococcus
pneumoniae (S. pneumoniae) are the only two streptococcal species that have the ability to
produce NadC. It was also suggested that the presence of NadC may be related to the
increased virulence of S. pyogenes and S. pneumoniae when compared to other avirulent
and opportunistic streptococcal species (1). Several NadC homologs have their structures
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determined. They have been identified in eukaryotic species including humans (hsNadC;
PDB code: 3LAR; 40% sequence identity; RMSD: 1.4Å over 264 Cα atoms) and
Saccharomyces cerevisiae (scNadC; PDB code: 3C2R; 35% sequence identity; RMSD: 1.7
Å over 247 Cα atoms). Pathogenic, non-streptococcal species for which a structure of
spNadC homolog was determined include: Vibrio cholerae (vcNadC; PDB code: 3PAJ;
45% sequence identity; RMSD: 1.5 Å over 267 Cα atoms), Salmonella enterica (stNadC;
PDB code: 1QAP, 41% sequence identity; RMSD: 1.9 Å over 262 Cα atoms),
Mycobacterium tuberculosis (mtNadC; PDB code: 1QPR; 40% sequence identity; RMSD:
1.3 Å over 272 Cα atoms), Helicobacter pylori (hpNadC; PDB code: 2B7N; 38 % sequence
identity; RMSD: 1.5 Å over 262 Cα atoms), and Franciscella tularensis (ftNadC; PDB
code: 3TQV: 36 % sequence identity; RMSD 1.4 Å over 262 Cα atoms).
According to the Pfam database, NadC is a part of a family of proteins that have an
 hydrolase fold (3, 4). This fold commonly contains a central parallel  sheet that is
composed of several beta strands which is flanked by -helices. NadC belongs to the TIMphosphate binding superfamily of proteins that are grouped by the presence of a TIM-barrel
structure containing the same 8  helical/ 8  strand feature described above in the 
hydrolase family (5, 6). The barrel-type fold corresponds to the C-terminal part of NadC,
while the N-terminal part of the protein contains an anti-parallel  sheet that is flanked on
one side by four helices (Figure 2.1).
This chapter will present the first structural information on native spNadC and
spNadC69A deletion mutant.
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2.2 RESULTS AND DISCUSSION
PROTEIN PRODUCTION
All QSEs were over-expressed and purified in high quantities. SpNadC isolation
resulted in approximately 240 mg of the protein per 1L of culture, as measured after an
immobilized metal affinity chromatography (IMAC) step. Protein purity was confirmed
using both SDS-PAGE and mass spectrometry. SpNadC contains a purification tag
composed of 25 amino acids that encodes for a tobacco etch virus (TEV) cleavage site.
Cleavage of this tag, with TEV however, was unsuccessful. SpNadC was further purified
by gel filtration, and the elution profile contained one single peak that corresponds to a
molecular weight of ~200 kDa. The same results were obtained for both the native and
mutated protein. Dynamic light scattering was also used to determine the molecular weight
of NadC69A oligomer in solution. Results from these experiments indicate the molecular
weight of NadC at 212 ± 80 kDa. These results indicate that most likely in solution spNadC
forms a hexamer.
KINETIC DATA
According to Sharma et al., mtNadC is proposed to operate in an ordered-sequential
mechanism with QA binding first and PRPP binding afterward (2) (Figure 2.2). It was
assumed that spNadC operates according to the same mechanism.
Following a strategy adapted from Cao et al., an activity assay was conducted for
native spNadC, as well as spNadC69A (7). The assay did show activity for both constructs
as evidenced by increasing absorbance values, at 266 nm, over a 10 minute span. Our
results indicate that spNadC did not follow classic Michaelis-Menten kinetics, but did show
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increased NaMN production with increasing PRPP concentrations from 0.2 mM – 1.6 mM.
An inhibitory result was identified as the QA concentration was increased from 2-20 µM.
It should be noted that the QA concentration is significantly smaller, in this experiment,
compared to the PRPP experiments. The inhibitory outcome was also not observed with
kinetic results from homologs in the literature (2, 7).
Initial spNadC kinetics studies indicate that this enzyme is very inefficient, which
is consistent with previous studies (1). However, in the case of the protein used in this
study, it was observed that increased concentration of QA leads to enzyme inhibition. The
differences in the results of kinetics studies may be related to the presence of the
purification tag in the protein that was produced. Recombinant NadC used by Sorci et al.
contains a short, non-cleavable His×6 purification tag, while the uncleaved purification tag
used in these studies is 25 amino acids long. It was reported that in some cases the presence
of the purification tag may significantly affect protein activity and other functional
properties (8, 9). Assuming that the purification tag impacts the activity of NadC for the
kinetic studies it will be necessary to produce a recombinant protein without any additional
amino acids, or with a short purification tag as described previously (1).
NADCDE ACTIVITY ASSAY
Despite the fact that the NadC activity was impaired, it was possible to show that
NadC, NadD and NadE are able to produce NAD+. The reaction mixture containing all
QSEs and supplemented with MgCl2, NH4Cl, ATP, phosphoribosyl pyrophosphate (PRPP)
and quinolinic acid was shown to produce NAD+. This result prompted us to investigate
whether the enzymes are present in solution as separate molecular entities or whether they
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form higher order molecular assemblies. Each of the isolated QSEs were tested on a gel, in
non-denaturing conditions, to check whether such high order molecular assemblies are
formed. The results of these experiments clearly indicate that while all NadC, NadD and
NadE are present in solution in an oligomeric form, the formation of binary or tertiary
complexes between these enzymes does not take place in conditions that were used for the
experiment (Figure 2.4).
THERMAL STABILITY
Differential scanning fluorimetry studies have shown that native spNadC is more
stable than the mutant construct. SpNadC remained most stable in conditions at high
salinity (1 M NaCl) and high pH (pH 9.5) and remained stable until the experiment
temperature reached 60 °C (Figure 2.6). SpNadC69A was most stable in high salinity (1
M NaCl), slightly alkaline (pH 7.5-8) conditions and remained stable up to a temperature
of 58 °C (Figure 2.7). It should be noted that while the numerical difference between the
melting temperatures of each protein is only a difference of 2 °C, while the number of
conditions that were identified to provide stability up to ≥ 56 °C varied greatly. Native
spNadC results showed 18 conditions (mostly 250 mM- 1M NaCl, pH 7.0-9.5) with
melting point temperatures ≥ 56 °C, while spNadC69A only showed stability in only two
conditions within that range.
This cost-effective screening technique can also be used for identification of small
molecular compounds that promote thermal stability of a protein (10, 18). Use of this
approach resulted in identification of conditions in which protein was more stable, and such
conditions were used during protein purification and for protein storage. The dialysis buffer
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conditions that were chosen to store spNadC were: 150 mM NaCl and 0.05 M Tris (pH
7.5).
CRYSTALLIZATION
Native NadC and NadC69A crystals were identified within 48 hours of
crystallization setup. Crystals were identified in a variety of conditions including Index
Screen (Hampton Research, Aliso Viejo CA) condition numbers 18, 19, 26, 67, and 81,
Wizard Classic I (Rigaku, Bainbridge Island, WA) conditions 18, 38, and 48, and Wizard
Classic II (Rigaku, Bainbridge Island, WA) conditions 15 and 48 (Table 2.1). While crystal
formation was fast and plentiful, obtaining crystals that diffracted to a resolution higher
than 4.0 Å was very challenging. Despite the fact that the crystals appeared from various
solutions their morphology was always the same. The most promising condition (Index
screen condition # 67: 0.2 M ammonium sulfate, 0.1 M BIS-TRIS (pH 6.5), 25% w/v PEG
3350) was optimized to improve crystal quality. Optimization eventually led to producing
crystals that were from 5 to 250 microns in size.

The biggest improvement in

crystallization was achieved after use of the Hampton Research Additive screen (generous
gift from Dr. James Sodetz, University of South Carolina) and identification of NaBr as
the compound that improved crystal quality. The best crystals were grown from the
solution composed of 0.48 M ammonium sulfate, 0.1 M BIS-TRIS (pH 6.5), 20 % w/v
PEG 5000 and 1.25 mM NaBr. It was also identified that the NadC and NadC69A crystal
morphology was temperature dependent. At room temperature the crystals were cubeshaped, while at 4 ºC the crystals adopted an elongated shape (Figure 2.7). However, the
change of the crystal morphology did not have any effect on diffraction quality. The largest
crystals obtained were from a 1.1 M ammonium tartrate condition that produced crystals
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that were up to 500 microns. Unfortunately, the large volume of the produced crystals did
not correlate with improved diffraction quality. The most notable results were obtained
while conducting in situ proteolysis experiments (11). In these experiments, a protease,
trypsin specifically, was added in nanogram quantities to our protein stock solution directly
prior to crystal screening preparations. The goal of this procedure was to minimize the
entropy of the protein surface by cleaving the loop structures. As a result, we hoped to
improve the probability of crystallization. The result from these experiments also promoted
an increase in crystals size to approximately 500 microns. Additionally, in situ proteolysis
crystals were observed to have a “pitted” center (Figure 2.7). The direct cause of this
morphology is yet to be determined.
ANALYSIS OF NADC SEQUENCE
SpNadC contains 299 residues in each chain of the hexameric structure (1794 total
residues). The NCBI Protein BLASTsearch against homologous proteins found in the PDB
reveals that this each chain is composed of 2 regions: the dimer interface and the active site
(5). These results also include predicted residues of the active site (residues in bold are
highly conserved): T139-K141, H163, R164, D224, S247, G248 and dimer interface: S31,
T32, E105, R106, T142, L166, S167, M170, K173, N175, H176, A179, and A190
(5).Conservation of the NadC sequences is shown in Figure 2.8.
Using the Database of Prokaryotic operons (DOOR2) it was identified that the QSPs
are not found on the same operon, as it observed in Mycobacterium tuberculosis (12).
Database results indicate that, in reference to the origin of replication, the nadC reading
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frame is the farthest upstream of the QSPs. Results from DOOR2 show nadC at position
180951 to 181823 within the genome.
STRUCTURAL ANALYSIS
Diffraction results were first obtained from spNadC69A crystals grown in the
following conditions: (1) 1M ammonium phosphate, 0.1 M sodium citrate tribasic/citric
acid (pH 5.5), 0.2 M sodium chloride (Wizard Classic II, #33, Rigaku Bainbridge Island,
WA), and (2) 20% w/v PEG 6000, 0.1 M BIS-TRIS (pH 6.4), 0.48 ammonium sulfate, 1.25
mM sodium bromide. The crystal obtained using condition (1) belong to the cubic system
and P23 space group, while the conditions (2) lead to orthorhombic crystals with C222 1
symmetry. The orthorhombic crystals were obtained through optimization of the Hampton
Research Index screen condition # 67. The native NadC crystals were grown from solution
containing from 0.48 M ammonium sulfate, 25% w/v PEG 6000 and 0.1 M BIS-TRIS (pH
6.5). The cubic form contained four protein chains per asymmetric unit and the
orthorhombic form contained six protein chains per asymmetric unit. Data collection and
processing details are outlined in Table 2.2. Structure solution and refinement details are
outlined in Table 2.3.

OVERALL STRUCTURE

The first structure to be determined was the structure of the deletion mutant
(spNadC69A), and the presence of the deletion was discovered during model building. This
discovery prompted us to produce the native protein (spNadC) with the corrected sequence.
All determined spNadC structures revealed the presence of hexameric assemblies in the
crystals. This is in agreement with gel filtration, dynamic light scattering, and native gel
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results indicating that spNadC is a hexameric structure in solution. It is assumed the
hexamer observed in the crystal structure is the same hexamer found in solution. The
identified oligomeric structure may be treated as a “trimer of dimers”. The proposed
substrate binding site is formed by two protein chains that compose the dimer. The area of
interaction between chains forming the dimer is very large and is calculated to be 2623 Å2,
as calculated by PDBePISA (13).
The analysis of the NadC69A structure revealed that the protein fragment, which
should contain the missing alanine residue, is facing the opening located in the middle of
the hexamer (Figure 2.10). This protein fragment does not correspond to any secondary
structural element stabilized by hydrogen bonds, and the deletion does not impact the
overall structure of the protein. However, the thermal stability of the mutant is decreased
in comparison with the native protein. It is possible that the shortening of the loop region
containing A69 results in a strain of the protein backbone that leads to the decreased
mutated protein stability. It is also possible that the destabilization of the protein is related
to the fact that omission of the A69 brings together two acidic and negatively charged
residues (D68 and E70). The lack of any significant structural differences between the
native and the mutated versions of spNadC and the relatively remote location of the
deletion with respect to the active site explains why that both versions of protein display
very similar enzymatic activity.
ACTIVE SITE
Structural comparisons of spNadC with seNadC (PDB code: 1QAP) bound to QA
show that residues T139, R141, K141, H163, and R164 of spNadC are identical with the
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residues of the stNadC structure. (Figure 2.12). Comparisons with the mtNadC (PDB code:
1QPR) bound to substrate analogs, phtalic acid (PHT) (QA analog) and PPC (PRPP analog)
also indicates that the residues involved in QA and PRPP binding are highly conserved not
only in terms of sequence, but also in their structure (Figure 2.13). Sharma et al. suggested
that PRPP is bound to two Mg2+ ions which are considered responsible for stabilizing the
pyrophosphate region of PRPP (14). However, to date there have been no structures
determined with PRPP bound.
In mtNadC residues R105, R139 and R162 (which correspond to R106, R140 and
R163 in spNadC) are responsible for binding of QA while D173 and R48 residues along
with a series of coordinated water molecules bind to the phosphate group and metal ion on
the “pyrophosphate side” of PRPP. In mtNadC the nitrogen atom from the backbone of
G249, the carbonyl from A268, the nitrogen atom from G270, and the side chain of H274
are proposed to be involved in binding of the PRPP C5 phosphate group (14). No
mechanistic details for this reaction are available, but it is presumed that the nitrogen of
the pyridine ring of QA initiates a nucleophilic substitution (SN1) reaction on the + C3 of
PRPP to create the nucleoside bond forming NaMN and PPi (14). Structural comparisons
between spNadC and the homologs reported to the PDB also suggests that the QA and
PRPP binding sites are created from residues from one chain of the dimer and not from the
interaction of both chains together. Superposition of structures of homologous enzymes
from Homo sapiens, Salmonella enterica, and Mycobacterium tuberculosis also indicates
very similar substrate binding locations.
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CONCLUSIONS AND FUTURE DIRECTIONS
The crystal structure of spNadC was determined at 2.85Å resolution. The protein
forms a hexameric assembly that is present in both solution and crystal state. It is possible
that the N-terminal purification tag affects protein activity, as well as the quality of the
crystals. Therefore, the next step in the project will involve generation of a protein
construct with the purification tag located on the C-terminus. Moreover, lysine residues,
on the protein surface, will be mutated to alaine to increase the chance of obtaining the
high quality crystals diffracting to higher resolution. Such crystals are necessary for
elucidation of details of interactions between spNadC and its substrates. Polyhistidine tag
removal may also improve enzymatic activity of the enzyme; with the goal of observing
Michaelis-Menten kinetics in increasing QA and PRPP conditions, as it was observed in
the case of homologous proteins (2, 7). However, it cannot be excluded that the reaction
mechanism of spNadC may be different from those reported for the homologous proteins,
as the sequence identity between spNadC and the proteins that were characterized in terms
of their enzymatic activity is approximately 40%.
2.3 MATERIALS AND METHODS
PROTEIN PRODUCTION AND CRYSTALLIZATION
Genomic information on the QSEs were obtained from the Uniprot (15). Synthetic
genes with optimized codons were produced by DNA 2.0 (Menlo Park, CA) and introduced
into a vector bearing kanamycin-resistance pJexpress411. Each of the QSEs were designed
to contain an N-terminal purification tag (MHHHHHHSSGVDLGTENLYFQS↓GSG). The
purification tag includes a TEV-cleavage site (marked with an arrow). Each of the plasmids
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were introduced into competent BL21 (DE3) E. coli (New England Biolabs, Ipswich, MA),
and the cells were made competent using calcium chloride (17). The plasmids were
introduced using the heat/ cold shock method for bacterial transformation (18). Upon
transformation, the cells were grown on Luria Broth (LB) agar plates supplemented with
kanamycin, for 12 hours at 37 °C. Observations made the following day identified greater
than 100 pearl-white colonies. A single colony was transferred and cultured in 5 mL of
kanamycin-infused LB broth for 12-16 hours at 37 °C. After the 12-16 hour incubation, a
portion of the cultures were stored in a 40 % glycerol/LB media solution and kept at -80
°C. The remaining culture was used for transformation confirmation by DNA sequencing.
As it was previously mentioned, during model building it was discovered that the synthesis
of nadC gene resulted in omission of a codon and production of the spNadC69A deletion
mutant. The gene was re-synthetized, to insert the alanine codon into the DNA sequence,
by Genscript (Piscataway, NJ).
Overnight preparatory cultures of transformed BL21 (DE3) E. coli (New England
Biolabs, Ipswich, MA) were transferred into 1L of LB media, and allowed to rotate, at 250
RPM, for approximately 2.5 hours at 37 °C. When optical density (OD600) was achieved,
between 0.8 and 1.0, 200 µL of 1 M IPTG was added to promote protein over-expression
as outlined by Sorci et al. (1). The induced culture temperature was dropped to 18 °C and
allowed to rotate at 250 rpm for 12-16 hours (1).
Upon completion of the 12-16 hour culture, the culture media was spun at 10524 g
for 20 minutes at 4 °C using the Beckman Coulter Avanti J265 XPI centrifuge (Brea,
CA).The resulting cell pellet was weighed and stored at -80 °C. In preparation for isolation,
the cell pellet was re-solubilized in buffer containing: 500 mM NaCl, 150 mM Tris buffer
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(pH 7.5), 5 mM 2-mercaptoethanol, and 1x concentration of protease inhibitors (Thermo
Scientific, Waltham, MA). The cells were lysed, on ice, using the Branson 450 Sonifier.
Each cell pellet was sonicated in 10, 30 second, cycles, which included a 1 minute break
between cycles. The cell lysate was separated into soluble and insoluble fractions using the
Beckman Allegra X30 R centrifuge, at 3849 g, for 20 minutes. The soluble fraction was
decanted and centrifuged again using the Beckman Avanti J265 XPI centrifuge at 32264 g
for 20 min, at 4 °C. The soluble fraction was used for protein isolation, using the
immobilized metal affinity chromatography and Ni-NTA resin (Qiagen, Hilden, DE),
while the insoluble fraction was kept at -80 °C for analysis. The protein was eluted from
the column using an imidazole gradient of 5 mM, 60 mM, 250 mM, and 500 mM. Purity
of protein samples was confirmed by SDS-PAGE. The eluted protein solution was allowed
to dialyze overnight, at 4 °C, in buffer containing: 50 mM Tris, 150 mM NaCl, and 5 mM
2-mercaptoethanol. The dialyzed protein solution was further purified by size exclusion
chromatography. All size exclusion experiments were conducted on the AKTA™ Pure
(General Electric, Piscataway, NJ) using the Superdex 200 HiLoad 16/60 column. Buffer
conditions for these experiments were the same as for the dialysis buffer. The fractions
representative of the protein of interest were concentrated, divided into 1 mL aliquots, and
stored at -80 °C.
All initial crystallization experiments were performed using the sitting-drop vapordiffusion method. The initial screening utilized the 96 well Original Intelli 96-2 plates (Art
Robbins Instruments, Sunnyvale, CA). The well contained 80 µL of screening solution,
and the drops were formed by mixing of 1 µL of protein solution and 1 µL of screening
solution. Several commercial crystallization screens, Wizard Classic 1-4 (Molecular
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Dimensions/Rigaku, Altamonte Springs, FL) and Index (Hampton Research, Aliso Viejo
CA) for example, were used in the initial search of crystallization conditions.
Optimization experiments used both sitting and hanging drop techniques. Sittingdrop experiments used the 24-well Cryschem sitting-drop plate (Hampton Research, Aliso
Viejo CA). Each well contained 500 µL of crystallization solution, and the sitting-drop
contained 3 µL of 2 mg/mL protein and 3 µL of well solution. Hanging-drop experiments
utilized the Qiagen EasyXtal 15 well tool (Hilde, DE). The well contained 150 µL of
crystallization solution, and the screw cap contained 2 drops, 6 µL each, in the same
solution mixture as in the sitting-drop experiment Most of the crystallization experiments
were conducted at 25 °C, with fewer experiments conducted at 18 °C and 4 °C.
DYNAMIC LIGHT SCATTERING
Dynamic Light Scattering (DLS) was used to characterize a quaternary structure of
protein in solution. For DLS experiments, 2 mL of 2 mg/mL QSE was dialyzed for 12
hours in the dialysis solution described above. After dialysis, the QSEs were diluted to 0.2
mg/mL, using the dialysis buffer, and the sample was analyzed using the experimental
procedure for instrumental analysis, as outlined by protocol prepared by Malvern
(Worcestershire, UK) for the Zetaseizer ZS90.
DIFFERENTIAL SCANNING FLUORIMETRY
Differential Scanning Fluorimetry (DSF) was used for the determination of protein
thermal stability as well as the determination of the small molecular compounds influence
on protein stability (19). SYPRO-Orange is an additive that produces fluorescence when
bound to hydrophobic residues during protein denaturation (19, 20). In this experiment,
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proteins are heated incrementally, and the determination of their thermal stability is
indicated by the temperature at which they fluoresce.
Protein stability was initially checked by testing 96 different buffer conditions using
an in-house pH and salinity screen. The screen was designed to increase pH from 4.0 to 9.5
and increase NaCl concentrations from 0.0 to 1.0 M using a 96-well arrangement (19). A
chart displaying the buffer strategy is outlined in Figure 2.13. Sypro-Orange (Life
Technologies, Grand Island, NY) was first diluted 1:1000 in 1 mL of the QSE stock, at 2
mg/mL, and the protein solution was placed on ice. Ninety-six buffer solutions, increasing
in pH and NaCl concentration, were then added to their respective wells using the Biorad
(Hercules, CA) Hardshell 96-well PCR plate. Figure 2.14 provides a schematic describing
buffer conditions for each well. Using the BioRad (Hercules, CA) CFX96 real-time PCR
machine, a computer protocol was designed to vary the temperature of each well by 2 ºC/
min from 30 ºC to 90 ºC. Melting temperatures for the QSEs were determined by
fluorescence. Derivative results for protein melting points were calculated by the Bio-Rad
CFX96 software package. This protocol was adapted by Dr. Nicholas Mank (unpublished)
from the original work of Niesen et al. (19). The stability of QSEs was also tested in the
presence of various small molecular compounds. Experiment preparation was the same as
described above. All small molecule screening conditions were made soluble in aqueous
solution and were buffered with Tris to pH 7.5. A list of all 384 conditions is shown in
Appendix A.
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KINETICS
The enzymatic activity of spNadC was determined by a method outlined in the
study of a homologus quinolinate phosphoribosyl transferase in Salmonella tyhphimurium
(7). Briefly, activity reaction conditions, at a final volume of 1 mL, contained 50 mM
HEPES (pH 7.5), 6 mM MgCl2, 200 µM PRPP, 300 µM QA, and 20 µg of NadC. The
reaction time was 10 min per experiment. Reaction conditions for kinetic experiments
which involved testing the effect of increasing PRPP on the activity of spNadC maintained
the same activity assay concentrations, described above, with increasing amounts of PRPP
at the following concentrations: 200 µM, 400 µM, 600 µM, 800 µM, 1 mM, 1.2 mM, 1.4
mM, and 1.6 mM. The above experiment was repeated with increasing amounts of QA at
the following concentrations: 2 µM, 4 µM, 6 µM, 8 µM, 10 µM, 12 µM, 14 µM, 16 µM,
18 µM, and 20 µM. NaMN detection was measured using the Nanodrop 2000c (Thermo
Scientific, Waltman, MA) at 266 nm. Each experiment was done in triplicate, at 1 mL,
using a quartz cuvette, and NaMN biosynthesis was detected at 266 nm.
In a separate assay, biosynthesis of NAD+ was confirmed, at 340 nm, with the use
of all of the QSEs in one reaction solution. The reaction was conducted at 1 mL in a quartz
cuvette. The reaction solution contained: 50 mM HEPES (pH 7.5), 6 mM MgCl 2, 20 mM
KCl, 10 mM NH4Cl, 2 mM ATP, 0.2 mM phosphoribosyl pyrophosphate (PRPP), 0.36
mM quinolinic acid (QA), 2 µg bovine serum albumin (BSA), 1 % ethanol, 4 µg NadC, 4
µg NadC, 4 µg NadE, 10 µg alcohol dehydrogenase (ADH). The activity assay was run for
10 min. The success of this assay lead us to attempt a supplemental assay to determine the
effect of increasing NadC on the rate of NAD+ formation, although no conclusive results
have been obtained to date.
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DATA COLLECTION AND PROCESSING
Prior to the diffraction experiments spNadC and spNadC69A crystals were cryocooled. 10 % glycerol was used to cryo-protect the crystal grown from ammonium
phosphate, and no cryoprotectant was used for other crystals. Data was collected at the
Advanced Photon Source at Argonne National Laboratory in Lemont, IL. The data from
the NadC69 crystals were collected at Sector 22 belonging to the Southeast Regional
Collaborative Access Team (SER-CAT); beamlines 22 BM and 22 ID. Data for native
spNadC was collected at Sector 19 belonging to the Structural Biology Center; beamline
19 BM. All data collection was performed at 100 K. Data processing was performed using
HKL-2000 (21) and the details of the diffraction experiments are shown in Table 2.2.
STRUCTURE DETERMINATION AND VALIDATION
For each of the spNadC and spNadC69A structures HKL-3000 and MOLREP (21,
22) were used for structure determination. Both of the spNadC69A structures were solved
prior to the spNadC structure and molecular replacement was used for phasing. The P23
spNadC69A structure was solved first using the Homo sapiens NadC homolog (PDB code:
4KWV) as a starting model. The model of spNadC69A cubic form was used as a starting
point for determination of the orthorhombic C2221 form. Determination of native spNadC
structure was done by Fourier synthesis using the spNadC69A C2221 structure to calculate
phases. All structures were refined using HKL-3000 and Refmac (23), and models were
updated and validated using COOT (24). Final validation was done using Molprobity (25)
and CheckMyMetal (26). All of the spNadC and spNadC69A structures and structure
factors were deposited into the Protein Data Bank (PDB) and were given the accession
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codes 5HUL (spNadC69A - P23), 5HUO (spNadC69A - C2221), and 5HUP (native
spNadC). Summary information on model refinement and validation is included in Table
2.3.
OTHER COMPUTATIONAL METHODS
Other Computational methods include: the DALI database for protein structural
comparison studies (27); Xtalpred, for predicative studies on the likelihood of
crystallization of all of the QSPs (28); Protparam, for the determination of predicted
chemical parameters for all of the QSPs (29). PHYRE2 and SwissModel were used to
make predictions on the structural parameters for each of the QSPs through structural
homology calculations (30, 31). Pymol was used for structure structural studies and cartoon
and surface representations throughout this dissertation (32). Clustal Omega and ESPript
was employed for sequence alignment and secondary structure studies (33, 34). PDBePISA
was applied for the calculation of structural and thermodynamic parameters for each of the
QSPs (35). Consurf was used for the determination of residue conservation for all of the
QSPS, as well as provided structural representations for this conservation for display in
Pymol (36).
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2.4 TABLES AND FIGURES
Table 2.1: Crystallization conditions for spNadC and spNadC69A identified during an
initial screening.
Screen
Index

Wizard
Classic I

Wizard
Classic II

Condition # Condition contents
18
0.49 M sodium phosphate monobasic monohydrate, 0.91 M
potassium phosphate dibasic (pH 6.9)
19
0.056 M sodium phosphate monobasic monohydrate, 1.344 M
potassium phosphate dibasic (pH 6.9)
26
1.1 M ammonium tartrate (pH 7.0)
67
0.2 ammonium sulfate, 25 % w/v PEG 3350, 0.1 M BIS-TRIS
(pH 6.5)
81
0.2 M ammonium acetate, 25 % w/v PEG 3350, 0.1 M HEPES
(pH 7.5)
18
1.0 M potassium sodium tartrate, 0.2 M sodium chloride, 0.1
M imidazole (pH 8.0)
38
0.2 M lithium sulfate, 1.0 M potassium sodium tartrate, 0.1 M
CHES (pH 9.5)
48
20 % w/v PEG 1000, 0.2 M zinc acetate, 0.1 M sodium
acetate/ acetic acid (pH 4.5)
15
1.26 M ammonium sulfate, 0.1 M HEPES (pH 7.5)
48

1.0 M potassium sodium tartrate, 0.1 M MES (pH 6.0)
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Table 2.2: Summary of spNadC and spNadC69A data collection and processing.
Protein

spNadC69A

spNadC69A

spNadC

PDB accession code

5HUL

5HUO

5HUP

Diffraction source

APS (21 ID)

APS (22 BM)

APS (19 BM)

Wavelength (Å)

1.000

1.000

1.000

Detector

Rayonix
MX300HS
380

Rayonix MAR 225

ADSC Q210r

280

270

Rotation range per image (°)

0.5

1.0

0.5

Total rotation range (°)

100

200

100

Exposure time per image (s)

1

1

1

Space group

P23

C2221

C2221

a, b, c (Å)

179.6, 179.6,
179.6

106.2,186.3, 221.9

108.2, 189.0,
222.4

Resolution range (Å)
σ Cutoff

40- 2.85
(2.95- 2.85)
-3 

40- 2.80 (2.852.80)
-3 

50.00- 3.45
(3.46- 3.40)
-3 

Total No. of reflections

44917 (2166)

54566 (2658)

26521 (1389)

Completeness (%)

99.8 (99.5)

100 (100)

90.3 (95.2)

Redundancy

4.7 (4.6)

8.4 (8.5)

3.8 (3.9)

〈I/σ(I)〉

24.1 (2.0)

14.6 (2.3)

7.9 (1.8)

Rr.i.m.

0.129 (0.990)

0.162 (0.958)

0.140 (0.790)

Rp.i.m.
Overall B factor from Wilson
plot (Å2)
CC ½

0.055 (0.434)
84.6

0.056 (0.331)
64.6

0.071 (0.389)
45.3

(0.573)

(0.791)

(0.729)

Crystal-to-detector distance
(mm)
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Table 2.3. Summary of spNadC and spNadC69A structure refinement statistics.

Protein

NadC69A

NadC69A

Native NadC

Resolution range (Å)
Completeness (%)

39.23- 2.86
(2.92- 2.85)
99.72 (99.6)

37.01- 2.80
(2.87- 2.80)
99.92 (100)

50- 3.45 (3.543.45)
82.40 (72)

 Cut-off

0

0

0

No. of reflections,
working set
No. of reflections, test
set
Final R

42638

51691

23687

2268

2768

1271

0.222

0.220

0.303

Final Rfree

0.246

0.258

0.348

No. of non-H atoms

8629

13034

12565

Protein

8517

12798

12454

Ligand

16

20

17

Solvent

96

216

94

Bonds (Å)

0.012

0.012

0.011

Angles (°)

80

53

84

Protein

81.5

54.0

88.3

Ligand

86.1

85.1

85.1

Most favored (%)

96.6

96.7

93.5

Allowed (%)

100

99

99.5

Chain A

6- 288

6- 288

6- 288

Chain B

6- 288

6- 288

6- 288

Chain C

6- 288

6- 288

8- 289

Chain D

5-288
6- 288

6- 289

cryst

R.m.s deviations

Average B factors (Å2)

Ramachandran plot

Visible Residues

Chain E
Chain F

5-289

Chain H

6-289
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Figure 2.1: The spNadC monomer. This is a cartoon representation of a single chain of
spNadC shown in three different orientations. The N-terminus is shown in black, the Cterminus is colored orange.
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Figure 2.2: Cleland diagram describing ordered-sequential reaction. This diagram shows
an overview of an ordered-sequential reaction proposed for spNadC as based on Cao et al.
(7, 35). This schema is shown using the Cleland notation (35). “A” corresponds to PRPP;
“B” corresponds to QA; “P” stands for NaMN (released); “Q” describes CO2 and PPi
(released).
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Figure 2.3: Native gel electrophoresis of spNadC, spNadD, and spNadE. These results are
of the native gel electrophoresis for the experiments testing formation of higher order
molecular assemblies between NadC, NadD and/or NadE. No complex formation was
observed.
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Figure 2.4: DSF experimental outline. This outline displays the buffer conditions within
the 96-well plate for DSF/ Thermal stability experiments. These conditions were used for
testing of protein thermal stability in conditions with various pH and NaCl concentrations.
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Figure 2.5: Thermal stability results for spNadC69A. This chart depicts exemplary results
of a single differential scanning fluorimetry experiment for spNadC69A.
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Figure 2.6: Thermal stability results for spNadC. This chart depicts results of a single
differential scanning fluorimetry experiment for wild-type spNadC.
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Figure 2.7: SpNadC crystals with various morphologies. These figures show wild-type
spNadC crystals with different morphologies obtained in various conditions. The leftmost
picture displays the “pitted” center identified in in situ proteolysis conditions, the middle
figure displays the results of crystallization at 4 ºC and formation of an elongated spNadC
crystal. The right figure displays the most common spNadC crystal morphology observed
for crystals grown at 25 °C.
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Figure 2.8: SpNadC sequence alignment. Sequence alignment for spNadC and homologous
proteins which have their structures determined. The alignment was done using the ESPript
3.0 and CLUSTALW. SpNadC homologs originate from Vibrio cholerae (vcNadC),
Salmonella enterica (stNadC), Mycobacterium tuberculosis (mtNadC), Homo sapiens
(hsNadC), Franciscella tularensis (ftNadC), Helicobacter pylori (hpNadC), and
Saccharomyces cerevisiae (scNadC).
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Figure 2.9: SpNadC structure. Cartoon representation of the hexameric assembly of
spNadC
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Figure 2.10: SpNadC69A structure. Cartoon representations of the hexameric assembly of
NadC69A with (left) and without (right) secondary structure elements. Areas highlighted
in yellow define the locations of D68 and E70 residues. Areas highlighted in red are
proposed substrate binding sites.
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Figure 2.11: Generalized spNadC reaction.
spNadC.
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Schematic of the reaction catalyzed by

C

B
A

Figure 2.12: SpNadC with modeled inhibitor molecules. This cartoon representation shows
structural features of spNadC. Section “A” is representative of the complete spNadC
hexameric assembly; section “B” shows an spNadC dimer magnified and superposed with
a homologous dimer from mtNadC (PDB code: 1QPR) to show the predicted site active
site for spNadC (mtNadC is also hexamer); section “C” shows the magnified active site
and displays residue similarities between each structure. The residue numbers describe the
amino acids from the spNadC structure only.

48

C

B
A

Figure 2.13: SpNadC with modeled substrate. This cartoon representation shows structural
features of spNadC. Section “A” is representative of the complete spNadC hexameric
assembly; section “B” shows an spNadC dimer magnified and superposed with a
homologous dimer from stNadC (PDB code: 1QAP) to show the predicted site active site
for spNadC (stNadC is a dimer); section “C” shows the magnified active site and displays
residue similarities between each structure. The residue numbers describe the amino acids
from the spNadC structure only
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Figure 2.14: Putative spNadC QA binding pocket. This figure shows a surface
representation of spNadC (left) and hsNadC (PDB code: 5AYY) (right) and the QA binding
pocket. For spNadC, the position of the QA was modeled using the hsNadC structure. QA
is shown in stick representation.
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CHAPTER 3
STRUCTURAL STUDIES OF NICOTINATE MONONUCLEOTIDE ADENYLYLTRANSFERASE
(NADD) OF THE GAS QUINOLINATE-SALVAGE PATHWAY
3.1 INTRODUCTION
SpNadD is the second of the trio of proteins, within the QSP, that is responsible for
the conversion of NaMN and ATP into NaAD (1) (Figure 3.1). According to the Database
for Essential Genes (DEGG) and available literature, the expression of the nadD gene is
integral for the survival of various pathogenic bacteria (1, 2). Moreover, the fact that
human homolog of NadD and spNadD have only 20% sequence identity makes the S.
pyogenes protein an attractive target for development of antimicrobial compounds. NadD
is a member of the nucleotidyl transferase superfamily of proteins (3). A signature
trademark of this superfamily is the presence of a (T/H)XGH motif that has been observed,
to play a part in the binding of ATP within the active site (Figure 3.2) (4). Other members
of this superfamily include adenyltransferases, tRNA synthetases, panthothenate
synthetase, ATP sulfurylases and cytidylyltransferase. As reported by Interpro, a common
characteristic feature of this superfamily is the presence of the Rossman-like //
sandwich fold (5). Despite the fact that NadD proteins have very similar overall fold they
may form different oligomeric structures. For example these proteins were reported to have
dimeric Staphylococcus aureus NadD (PDB code 2H29), tetrameric Bacillus subtilis NadD
(PDB code: 1KAM) or hexameric Homo sapiens NadD (PDB code: 1KR2) quaternary
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structures (4, 6, 7). The Escherichia coli homolog of NadD (ecNadD; PDB code: 1K4M),
has been observed to come in two forms: monomeric in the apo, and trimeric in the
substrate-bound form (9). However, the trimeric form has only been observed in crystal (9)
(Figure 3.3).
This structure of spNadD has yet to be determined. This chapter will present results
of protein production, crystallization, thermal stability, initial structural results, and
homology modeling.
3.2 RESULTS AND DISCUSSION
PROTEIN PRODUCTION
Recombinant spNadD was successfully expressed and isolated at a yield of ~50
mg/ L of culture. SDS-PAGE results indicated that isolation of spNadD was approximately
95% pure after gel filtration. Polyhisitdine tag cleavage experiments were successful for
spNadD, and it was the only QSP for which the purification tag could be removed. Results
of gel filtration experiments suggests that spNadC form a trimer in solution. These results
were consistent with the dynamic light scattering and native gel electrophoresis
experiments. The molecular weight of spNadD, as determined by DLS, was approximately
72 (± 9.7) kDa, while the molecular weight of a single spNadD chain is 24 kDa. Native
Gels tested to determine QSE complex formation also indicate that spNadD is trimer and
does not form a complex with either of the other QSEs (See Chapter 2, Figure 2.3).
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THERMAL STABILITY
Analysis of the protein thermal stability in solutions with varying pH and NaCl
concentration showed that spNadD was most stable in conditions with high salinity and
alkaline pH (Figure 3.4). There was no significant difference in the thermal stability of
spNadD with the purification tag compared to the protein with the cleaved tag (Figure 3.5).
The thermal stability studies revealed that various compounds may increase the
melting temperature of spNadD. For example, alanine, aminobiphenyl (in 15% DMSO),
cysteine, ferrous sulfate, malate, sodium pyruvate, and succinate promoted NadD stability
up to 60 °C (relative to the control conditions in which protein melted at 50 °C). Cadmium
chloride, Fast violet B salt, magnesium chloride, and sodium bromide promoted stability
up to 62 °C. Potassium tetrachloroplatinate, provided the greatest amount of stability at 64
°C (Figure 3.6).
CRYSTALLIZATION
Crystals of spNadD with and without purification tag may be obtained using the
following conditions: 1) 0.1 M succinic acid, 15% w/v PEG 3350 2) 20% w/v PEG 3350
and 3) 20% w/v PEG 3350, 0.2 M MgCl2, 0.1 M Tris (pH 8.5) (Figure 3.7). Crystals for
this protein, in all conditions, have long crystallization periods ranging from 2 weeks to 4
months. Crystals in the succinate condition produced irregularly-shaped clusters. Crystals
in the conditions in 2 and 3 produced long, hexagonal prism-shaped crystals. Crystals
obtained using condition #3 produced the best diffraction data. Various attempts to
improve quality of the crystals failed. For example, attempts to crystallize protein in
presence of substrate and substrate analogs were unsuccessful. Addition of the compounds
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that were identified to increase the thermal stability of NadD also did not improve the
quality of crystals. The protein was successfully modified using the reductive methylation
of lysine. However, the methylated protein could not be crystallized. Work is currently
being conducted to further optimize the conditions for crystal growth and identify solutions
that would promote crystal growth when the protein is in complex with its substrates.
ANALYSIS OF NADD SEQUENCE
According to the DOOR2 the nadD gene is located further downstream from nadC
gene, with respect to the origin, at position 275946-276578. SpNadD is the smallest of the
QSPs with only 210 residues in the polypeptide chain. Sequence analysis results suggest
that the areas with the highest sequence conservation, between NadD homologs with
known structures, include residues: 30-44, 60, 78-81, 103-110, 128, 131, 138, 144, 154,
155, 182, and 199, 202, 208, and 209. Most of the conserved residues between 30- 138 are
affiliated with the active site. According to Uniprot and Pfam spNadD contains the CTP
transferase-like domain that is composed of residues 28-183. NCBI Protein BLAST results
provide predicted locations of two major segments within the sequence: the active site
(substrate stabilizing) segment, and the (T/H)XGH motif. The sequence analysis suggests
that the active site residues include: L29, G30, G31, N32, H37-H40 (T/H) XGH motif),
V43, P64, S105, Y106, T107, F125, I127, G128, D130, M131, D138, W138, H139, Q154,
R155, and I176. The (T/H)XGH motif residues in spNadD include H37, N38, A39, and
H40. The residues are highlighted in bold to indicate that they are highly conserved. Refer
to Figure 3.8 for spNadD sequence alignment and residue conservation results with NadD
homologs with known structures.
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INITIAL STRUCTURAL ANALYSIS
CRYSTAL STRUCTURE
The best crystal of spNadD with cleaved purification tag diffracted only to 8.5 Å
resolution. The low resolution data suggests that the protein crystallized in a monoclinic
system and P21 space group. The unit cell parameters were identified as: a =104Å, b =103
Å, c =114 Å,  =108º. Analysis of the probable solvent content using the Matthews
coefficient indicates that between 4 to 12 copies of spNadD are present in the asymmetric
unit (10). Gel filtration analysis, native gel analysis, and DSL results indicate that spNadD
is a trimer. Therefore, taking into account information on the crystal symmetry, the
oligomeric state of the protein and the solvent content most likely the unit cell contains 6,
9 or 12 protein chains in the asymmetric unit.
HOMOLOGY MODELING AND ANALYSIS OF THE MODEL
The PHYRE2 server was used to calculate homology models for the spNadD.
PHYRE2 reports the model results with structural quality parameters for confidence,
coverage, and identity. PHYRE2 defines confidence as “the probability that your (input)
sequence and the template are homologous”. The top four homology models used as
templates were from Bacillus anthracis (baNadD; PDB code: 3E27), Bacillus subtilis
(bsNadD; PDB code: 1KAM), Staphylococcus aureus (saNadD; PDB code: 2H29), and
Pseudomonas aeruginosa (paNadD; PDB: 1YUN). Each of the homologs had confidence
values of 100%, coverage of ≥ 88%, and identity of ≥ 33%. Cartoon representations of
these structures are shown in Figures 3.9 and 3.10. RMSD values between the NadD
homology model, built from a Bacillus anthracis template (PDB code: 3E27), against the
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top four homology models were: 1.2 Å for the saNadD model, 1.5 Å for the ecNadD model,
1.5 Å for the bsNadD model and 1.8Å for the paNadD model. Structural comparisons show
the greatest variability in the orientation of the loop regions, but the the secondary structure
elements forming structure the core of the protein are the same in all generated models.
NADD ACTIVE SITE PREDICTION
To gain insight into the active site location we compared structures of spNadD
homologs (saNadD, baNadD, mtNadD and bsNadD). It was observed that each monomer,
shows NaAD bound in similar locations. The adenylate moiety of NaAD is observed to
bind closer to the N-terminus which allows for stabilization by the highly conserved
(T/H)XGH motif, described above. For the spNadD model and the homologs the motif is
commonly found with in the first 20 residues, from the N-terminus of the structure.
Specifically, the motif for spNadD is “HNAH”, “HTAH” for saNadD, “HNGH” for
bsNadD, “HYAH” for saNadD, and for baNadD and mtNadD for it is “HGYH”. The
notable aspect of this motif is the orientation of both of the histidine residues, as they are
always oriented toward the adenlylate, located deep within the site. The acidic residues of
the motif are oriented toward the protein surface. Refer to Figure 3.11 and 3.12 for a
cartoon depiction of the binding pocket in open and closed conformations. Superposition
results for spNadD homology model versus the structural homologs reveal that there is
residue consistency, compared to spNadD residues described in Section 3.2.4, between
structures with variability in residue orientation dependent upon what is in the active site.
The orientation of the baNadD structure (PDB code: 3HFJ) with the inhibitor-bound does
show a major difference in residue orientation, but the binding site for the inhibitor
molecule is in a different location than the NaAD site. Contrary to this exception, the
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remaining structure results give confidence that the homology model could be an accurate
depiction of this protein and it is assumed that spNadD will contain the same active site
location.
CONCLUSIONS AND FUTURE DIRECTIONS
NadD continues to be the most elusive of the QSPs for structure determination, yet
may be one of the most critical primary targets for inhibitor development (8). Experimental
data has determined is that the protein is extremely stable, but difficult to crystalize
efficiently. Similar to results obtained by Zhang et al., from a homologous NadD construct
from E. coli, show that it can take weeks to grow crystals (9). Difficulties with
inconsistency, with manual preparation, can make it a challenge to quickly observe changes
to crystal formation, and optimize in an efficient manner. To overcome this two strategies
were employed to decrease general entropy of the protein in order to improve the likelihood
of crystallization. In first strategy, we decided methylate the lysine residues in all of the
QSPs in order to improve the probability of crystallization and/or change crystal
morphology in order to improve diffraction for higher resolution results. The second
strategy targeted the mutation of the lysine residues to improve the formation of crystal
contacts. We utilized the SERp server (UCLA) to identify target lysine residues for
mutation in order to decrease overall protein entropy (11). Results from the server indicate
that lysine residues 44-45 and residues 210-211 (in DNA 2.0 optimized sequence) were
prime targets for mutation (11). Using the NCBI Protien BLAST server, these residues
were also determined to not interfere with residues involved with active site binding (11,
12, 13). Future experiments will utilize molecular cloning to mutate lysine residues into
alanine residues thus creating three NadD mutant constructs. These NadD constructs will
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have mutations at residues 44-45 only, 210-211 only, and a double mutant will have
substitutions at both sites at both sites. By decreasing entropy we hope to create protein
constructs that will afford a more efficient means of crystal formation, for higher quality
crystals for eventual x-ray analysis.
3.3 MATERIALS AND METHODS
PROTEIN PRODUCTION AND CRYSTALLIZATION
All protocols for protein production, isolation, and crystallization experiments are
consistent with the experimental protocol outlined previously in Chapter 2, pages 27-30.
In addition, for the purpose of crystallization spNadD was methylated. The reductive
methylation of lysine was performed using a protocol outline previously (14). Briefly, each
the QSPs were stored at -80 °C in 2 mg/mL concentrations for crystallization and were
thawed, on ice, prior to the methylation experiment. The protein solutions were initially
diluted two-fold in dialysis buffer (50 mM Tris (pH 7.5), 150 mM NaCl, and 5 mM 2mercapto-ethanol). The solution was then placed in an ice bath for 30 min. After ice bath
incubation, 50 µL of 85 mM formaldehyde (diluted from 1 M stock in dialysis buffer) was
added to the protein solution and was gently mixed. Afterward 25 µL of 1 M BoraneDimethylamine (BDA) complex was added to the solution, mixed gently and returned to
the ice bath for two hours. After the two hour incubation, the formaldehyde and BDA was
added again to the protein solution at the volumes described above, and was returned to the
ice bath for an additional hour. Upon completion of the hour long incubation 20 µL more
of BDA was added and left at 4 °C for 12-16 hours. After the overnight incubation, 1-2 mg
of solid glycine was added and was placed in the ice bath for an additional hour. Upon
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completion the solution was concentrated and buffer exchanged in preparation for MALDI
analysis for confirmation of experiment success.
DYNAMIC LIGHT SCATTERING
All protocols for dynamic light scattering experiments are consistent with the
protocols outlined previously in Chapter 2, page 30.
DIFFERENTIAL SCANNING FLUORIMETRY
SpNadD thermal stability experiments were conducted using the Differential
Scanning Fluorimetry strategy outlined in Chapter 1, pages 30-31.
The thermal stability studies of spNadD in the presence of various small molecular
compounds were performed using the same approach as in the case of the pH vs. salinity
studies. The difference in the protocols was that the pH and salinity buffer solution was
exchanged with 10 µL of buffered small molecule solutions (0.05-0.1 M Tris pH 7.5).
Contents of each of the 384 conditions are contained in Appendix I. This protocol was
prepared by Dr. Nicholas Mank, which was adapted from the original work of Niesen et
al. (15). The conditions were prepared by an undergraduate volunteer Vincent Klapper.
DATA COLLECTION AND PROCESSING
SpNadD crystals were cryo-cooled in 10 % ethylene glycol, frozen in liquid
nitrogen and placed in a puck. All spNadD data were collected at the Advanced Photon
Source at Argonne National Laboratory in Lemont, IL. The diffraction experiments were
conducted remotely on the 22ID beamline run by the Southeast Regional Collaborative
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Access Team. All diffraction data was collected at 100 K, and results were processed using
HKL-3000 (16).
OTHER COMPUTATIONAL METHODS
All other computational methods used are consistent with the methods used in
Chapter 2, page 33.

64

3.4 TABLES AND FIGURES

Figure 3.1: General reaction for spNadD: This figure is a schematic of the reaction
catalyzed by NadD.
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Figure 3.2: The (T/H)XGH motif. Cartoon representation of a single Bacillus subtilis NadD
chain. The magnified region depicts the position of the (T/H)XGH motif and its orientation
to the adenylate moiety of NaAD.
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Figure 3.3: Proposed structure of spNadD. Trimer structure from ecNadD (PDB code:
1K4M, 37 % identity) is suggested to be the predicted oligomeric assembly for spNadD.
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Figure 3.4: Thermal stability results for uncut spNadD. This figure shows the results of
average denaturation temperatures, for his-tagged spNadD, in various pH and salinity
conditions during thermal stability experiments. Each DSF experiment was done in
triplicate.
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Figure 3.5: Thermal shift results for cut spNadD. This figure shows the results of average
denaturation temperatures, for spNadD with a cleaved his-tag, in various pH and salinity
conditions during thermal stability experiments. Each DSF experiment was done in
triplicate.
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Top 20 Small Molecule Stabilizers of spNadD
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Figure 3.6: NadD small molecule stability. Thermal stability results of the top 20 stabilizers
out of 396 total small molecule conditions.
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Figure 3.7. NadD crystallization results. These are images of NadD crystals grown form
0.1 M succinic acid, 15% w/v PEG 3350 (left), 20% w/v PEG 3350 (middle), and 20% w/v
PEG 3350, 0.2 M MgCl2, 0.1 M Tris (pH 8.5) (right).
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Figure 3.8: SpNadD sequence alignment. This figure shows the sequence alignment of
spNadD and homologous proteins that have their structures deposited to the PDB. NadD
homologs originate from the following organisms: Bacillus anthracis (baNadD),
Mycobacterium tuberculosis (mtNadD), Staphylococcus aureus (saNadD), Bacillus
subtilis (bsNadD) and Burkolderia thailandensis (btNadD). The area highlighted in black
box is the location of the highly conserve (T/H) XGH motif that is characteristic of proteins
in the nucleotidyl transferase superfamily (3).
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Figure 3.9: SpNadD homology model. Cartoon representations of spNadD model based
on Bacillus anthracis NadD structure (PDB code: 3E27). Areas highlighted in red (left)
indicate sites on the model that are considered highly conserved.
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Figure 3.10: SpNadD homology models. Cartoon representations of various spNadD
models. The model in green was generated using the baNadD structure (PDB code: 3E27)
as a template; the orange model was generated using bsNadD structure (PDB code:
1KAM), the gray model was generated using saNadD structure (PDB code: 2H29), and the
blue model was generated using paNadD structure (PDB code: 1YUN) as a template.
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Figure 3.11: SpNadD structural homolog active site comparisons. This figures show
comparisons the of active site locations on single NadD chains for proteins originating
from Staphylococcus aureus (saNadD-green), Bacillus anthracis (baNadD-cyan),
Mycobacterium tuberculosis (mtNadD) and Bacillus subtilis (bsNadD). Each of the
structures contain a NaAD molecule within the site, except for the bsNadD structure which
contains an inhibitor molecule.
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Figure 3.12: SpNadD putative substrate binding pocket. Surface representations of
mtNadD (left) and bsNadD (right) showing open and closed formations of the active site
in the presence of NaAD. The area highlighted in the red is the location of the (T/H)XGH
motif to show its orientation relative to the adenylate moiety of NaAD.
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CHAPTER 4:
STRUCTURAL AND FUNCTIONAL STUDIES OF STREPTOCOCCUS PYOGENES NH3-DEPENDENT
NAD+ SYNTHETASE (SPNADE)
4.1 INTRODUCTION
SpNadE is the responsible for the formation of NAD+ by the catalyzing the last step
of the QSP responsible for the conversion of NaAD and ATP into NAD+ (Figure 4.1) (1).
This enzyme is relatively well studied, and proteins from Bacillus anthracis, Bacillus
subtilis, and Escherichia coli are characterized functionally and structurally. (2, 3, 4).
Proteins originating from Burkholderia pseudomallei, Deinococcus radiodurans,
Pseudomonas aeruginosa, and Vibrio cholarae have their structures determined, but there
are no publications describing these enzymes.
SpNadE also belongs to the Adenosine Nucleotide -Hydrolase (AANH)
Superfamily (6, 7, 8). Proteins in this superfamily have Rossman-like alpha/beta/alpha
sandwich fold (InterPro code: IPR014729) and are characterized by the presence of a “PPloop” commonly found close to the N-terminus of the protein (8). In this loop a “SGGXD”
motif is commonly found which is considered to be important for phosphate binding (8).
Other proteins within this superfamily include: GMP synthases, tRNA methyl transferases,
and arginosuccinate synthases (8).
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Previous studies have identified NadE homologs as dimeric proteins (2, 3, 4). The
dimer has two binding sites for ATP and two binding sites for NaAD (2, 4). The ATP
binding site is contained within a single protein chain, while NaAD binding site
corresponds to a lateral cleft stretching across both protein chains (2, 4). The formation of
NAD+ is proposed to operate in an ordered-sequential fashion with binding of ATP
occurring first, followed by the binding of NaAD for the initial formation of an NaADadenylate intermediate (3, 4). The adenylate intermediate has been shown to be stabilized
by interaction with two Mg2+ ions (4). Upon formation of the intermediate species, it is
presumed that a nucleophilic attack by the lone pair of free NH3 occurs at the C7 carbonyl
carbon of the adenylate species (2). This attack results in the release of AMP and inorganic
pyrophosphate (PPi) leaving NAD+ to be reduced for eventual NADH formation (2). This
incidence, by the action of NH3 only, has been identified in E. coli and B. subtilis.
NAD+ synthetases in Mycobacterium tuberculosis (mtNadE), Saccharomyces
cerevisiae (scNadE), and Homo sapiens (hsNadE) are glutamine dependent. Glutamine
acts as a -NH3 donor to promote the same nucleophilic attack as described above and leaves
NAD+, AMP, PPi, and glutamate as its end-products. (9). HsNadE and scNadE are
considered to be exclusive to glutamine while mtNadE has been shown to be able to utilize
both glutamine and NH3 (4, 9).
Rodionova et al. identified that the nadE gene is essential for bacterial survival
(10). In knockdown studies, using Mycobacterium smegmatis, they showed nadE (or
nadD) silencing produced diminished growth of the bacterium in culture (10). The
Database for Essential Genes (DEGG) also showed that NadE, from GAS, contains
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significant sequence alignment to essential, proteins produced in other pathogenic species
(i.e. S. aureus and V. cholarae) (11).
Therefore, NadE seems to be a promising new target for development of
antibacterial compounds. There is still very little information identified about this protein
in GAS. This dissertation provides the first information the kinetic activity of the protein,
as well as, the first structures of NadE originating from S. pyogenes.
4.2 RESULTS AND DISCUSSION
PROTEIN PRODUCTION
Recombinant spNadE was successfully produced in high quantities. It was
estimated that after the nickel-affinity chromatography there was, on average, 340 mg of
spNadE, per 1 L culture. The last step of protein purification involved size-exclusion
chromatography. As judged by the SDS-PAGE the protein purity was greater than 90%.
The results from the size-exclusion step indicate the presence of one major peak
corresponding to a spNadE dimer, when compared to commercial standards. These results
were consistent with DSL results that indicate presence of an assembly in solution with
molecular weight of 72 ±5.3 kDa. The molecular weight of a spNadE with the purification
tag is 34 kDa. Attempts to remove the purification tag, with TEV protease, were
unsuccessful.
NADE KINETIC DATA
At increasing NaAD concentrations, spNadE shows Michealis-Menten kinetics.
With spNadE at a 13 pmol concentration, results showed a Km of 375 µM. The kcat was
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4.16 s-1

and the kcat/ Km was 11.09 s-1 mM-1 (Table 4.1). At the sample protein

concentration, with increasing ATP, spNadE showed a Km of 304 µM , a kcat of 5.63, and
kcat/ Km of 16.55. At experiment concentrations of greater than 4 mM ATP, results showed
ATP in excess caused an inhibitory effect. All experiments were conducted in triplicate,
and these are the average values of each cuvette experiment. Kinetic results provide
evidence to support that this protein is the most efficient of the QSEs. There is no other
published data for spNadE kinetics and variability of results could be observed in
experiments prepared in vitro. It also cannot be excluded that the presence of the
purification tag may impact the enzymatic properties (12, 13). As mentioned previously,
the his-tag removal experiments were unsuccessful.
Experimental results from protein homologs from Bacillus anthracis (baNadE)
(58.5% sequence identity) indicate approximate Km values (Km(app)) for NaAD and ATP
are 152 µM and 289 µM, respectively; the Bacillus subtilis (bsNadE) homolog (56.7 %
sequence identity) reported a Km(app), for NaAD, at 179 µM and ATP at 196 µM (2, 14).
No data was given for kcat/ Km (2, 14). In comparison to our experimental results our
enzyme could be regarded to have a lower substrate affinity. Refer to Table 4.1 for a report
of the kinetic results for spNadE compared to homologs from Bacillus anthracis and
Bacillus subtilis.
THERMAL STABILITY
DSF experiments performed in conditions with various pH and NaCl
concentrations showed that the recombinant spNadE was more stable in low pH, high salt
conditions (pH 4.0-4.5 and 500 mM NaCl) (Figure 4.2).
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The results of the small molecules impact on protein stability indicate that the top
stabilizing molecules, mellitic acid and 2-pyridine sulfonic acid, increase thermal stability
of spNadE by 10 ° C as compared to the control (melting at 50 °C). Phenyl-2-thiourea and
tetraamine copper (II) sulfate stabilized spNadE up to 58 °C. Co-crystallization
experiments are currently being conducted to structurally confirm the binding of these
molecules.
CRYSTAL SCREENING AND OPTIMIZATION
Crystals were obtained from Crystal Screen 1 (Hampton Research, Viejo CA)
optimization experiments in the following condition: 0.1 M Tris (pH 8.5), 20% w/v PEG
4000, and 0.2 M magnesium chloride. In hanging and sitting drop preparations small,
needle-like clusters of crystals were obtained within 24 hours. While, these crystals were
not suitable for diffraction, it was later found that underneath the needle clusters, within
the same condition, were thin, rectangular, plate-like crystals (Figure 4.3). These crystals
diffracted well, yet appeared inconsistently. The data obtained from the plate-shaped
crystals allowed for the determination of the spNadE crystal structure to 2.5 Å and 2.1 Å.
Significant effort was placed into optimization of crystallization conditions. The
optimization attempts included crystallization in various temperatures, reductive
methylation of the protein (for details see Chapter 3, page 63), and use of various additives.
The additives used in these experiments could be divided into three groups. The first group
included spNadE substrates, products or their analogs. The second group contained
compounds, i.e. glycerol, that were introduced in order to slow-down the rate of
crystallization, and the third group included compounds that were increasing protein
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stability. Despite the fact, that thousands of crystallization experiments were performed no
significant improvement of the crystallization conditions was obtained.
ANALYSIS OF THE SPNADE SEQUENCE
Genomic analysis indicate that the reading frames for the QSEs are dispersed within
the genome, and are not expressed from the same operon (5). In other pathogenic bacteria
(i. e. Staphlyococcus aureus and Helicobacter pylori) the nadE reading frame was, also,
not found to be included on an operon with genes encoding for homologous QSP proteins.
(5). In GAS, when compared to the other QSEs, the nadE reading frame is located the
farthest downstream, from the origin, at position 1288286 to position 1289110. (5).
The spNadE sequence contains 283 amino residues per protein chain (566 total in
the dimer). An NCBI Protein BLAST search against sequences of proteins, with structures
deposited to the PDB, revealed the presence of five major protein segments: the active site,
the ATP binding site, the NAD+ binding site, the dimer interface, and the Mg2+ binding
site(s) (Figure 4.4) (16). In accordance with BLAST results, the ATP binding site is
considered to be composed of residues: 53-61 (LGISGGQDS; amino acids marked in bold
are highly conserved), 88-91, 150, 168, 197, and 217-219. The NAD+ binding site is
composed of residues: 53-56, 60-61, 89-91, 140, 144, 147-148, 150, 169, 174, 178-181,
184, 219-220, 222, 234. The residues of the dimer interface include residues: 33-34, 37,
39-41, 114-116,119-120, 123-124, 141, 145, 148-149, 151-153, 155-157, 159-160, 181182, 185-190, 193-194, 268-270. Magnesium binding residues include residues: 56, 60,
174 and 218. Areas of highest sequence conservation are between residues 53-61 and 143246. In NadE from GAS, there is a “SGGQD” motif, which corresponds to residues 56-
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60. It should be noted that BLAST results do show residue overlap between segments.
Substrate-bound spNadE structures will need to be determined to confirm this overlap.
Sequence alignment studies comparing spNadE and hsNadE, using Clustal Omega
(15, 16), reveal that the identity between these sequences is approximately 24% (Figure
4.5). The low similarity between these proteins gives confidence that spNadE would be an
optimal template for structure-based drug design.
STRUCTURAL ANALYSIS OF SPNADE
OVERALL STRUCTURE
The NadE structure bound to Mg2+ and SO42- ions (spNadEsulf) was the first of the
NadE structures to be determined (Figure 4.6). The protein crystallized in primitive
orthorhombic system and P212121 space group with two protein chains in the asymmetric
unit. The structure was determined at 2.5 Å resolution. An NadE homolog from Salmonella
typhimurium (PDB code: 3HMQ) was successfully used as the starting model for molecular
replacement. The structure of spNadEsulf was refined to 0.171 Rcryst and 0.225 Rfree. The
model of the structure includes a dimer and the protein chains include residues 9-214 and
229- 282. Residues 215-228 from the highly conserved active site loop, are missing in both
structures, which indicates that they are disordered in the absence of substrates. Similarly,
the polyhistidine tags were also not modeled, as there is no visible electron density that
corresponds to this fragment of the molecule. It is assumed that high entropy of the segment
was the cause of in ability to visualize the electron density through x-ray
crystallography.The model of NadEsulf was deposited to the PDB with accession code
5HUH.
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The NadEsulf structure was used as a starting model during determination of the
NadE apo structure (NadE-apo). The NadE-apo structure was determined at 2.1 Å
resolution, and the final model was refined to Rcryst value of 0.168 and an Rfree of 0.212
(Figure 4.7). The model included residues 9-96, 98-215, 228- 282 for each of the protein
chain forming the dimer present on the asymmetric unit. The model of NadE-apo was
deposited to the PDB with accession code 5HUJ.
The single chain of spNadE has primarily alpha helical character with 11 alpha
helices (68 % of secondary structure), 3 parallel beta strands (18%), and 2, 310 helices (13
%) (Figure 4.8, Figure 4.9). The sequence and structure based searchers revealed that there
are several spNadE homologs that have their structure experimentally determined.
Homologous NAD+ synthetases that had the highest sequence identity originated from
Salmonella typhimurium (PDB code: 3HMQ, 68 % sequence identity; stNadE),
Escherichia coli (PDB code: 1WXI, 65% sequence identity; ecNadE), Bacillus anthracis
(PDB code: 2PZA; 58% sequence identity; baNadE) and Bacillus subtilis (PDB code:
2NSY; 57% sequence identity; bsNadE) (18). Structure of these proteins were used to
identify putative substrate binding sites for spNadE, and gave the following RMSD values,
using Coot SSM superpose: 0.69 Å (over 251 Catoms) for stNadE; 0.62 Å (over 257 C
atoms) for ecNadE, 0.74 Å (over 254 C atoms) for baNadE, and 0.85 Å (over 254 C
atoms) for bsNadE. Figure 4.10 highlights the regions of the spNadE structure that are the
most highly conserved, based on sequence alignments from these homologs.
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QUATERNARY STRUCTURE
Gel-filtration and DSL results indicated that spNadE forms dimers in solution.
These results are in agreement with structural analyses that show the presence of a dimeric
assembly in the asymmetric unit. We assume that the dimer observed in the crystal
corresponds to the biological assembly of spNadE. According to PDBpisa calculations
(19.), the dimer interface for spNadE-apo covers 2407 Å2 and the same interface for
spNadEsulf covers 2407 Å2.
ACTIVE SITE
Sequence homology analysis, using NCBI Protein BLAST, in combination with
structural studies, indicate that there are approximately 18 residues responsible for the
architecture of the active site. Through analysis of the structure it was evident that there
was no electron density for 15 of the residues due to possibly high entropy in that region.
Through sequence homology studies of this region, specifically residues 215-223, it was
determined that these residues were highly conserved and make up a loop structure within
that region. Using a structural homolog from bsNADE (PDB code: 1EE1) we modeled the
loop into this region in order to obtain some impression of the activity of this loop within
this region (Figure 4.11). It should be noted that bsNadE (PDB code: 1EE1) structure was
one of the few structures that determined the orientation for the loop structure (20). This
loop has also been indicated in the stabilization of Mg2+ within the ATP binding site, as the
ATP binding site shares 3 residues with this site. The architecture of this site will be
discussed in greater detail in the next section. The residues for the loop of interest include
E215, K216, V217, P218, T219, A220, D221, L222, E223 from spNadE. In bsNadE
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residues include: L222, K223, E224, P225, T226, A227, D228, L229, and L230. Both
loops are have approximately 67% sequence identity.
SPNADE ATP/ Mg2+ BINDING
ATP and Mg2+ binding sites in NadE were shown to be composed of residues from
a single protein chain. Sequence homology studies of structural homologs of the spNadE
provide evidence to support that binding of the ATP occurs solely within the individual
chains of the dimeric assembly and not at the interface. Residues involved in the conserved
“SGGXD” motif, described above, are also is found at this site.
Sequence homology studies of spNadE identifies residues: L53, G54, I55, S56,
D60, S61, V89, R90, L91, R150, T168, K197, V217, P218, and T219 to be responsible for
the providing a binding pocket for ATP. Residues P218 and T219 (as well as any other
residues between 216-227) are not visible in the electron density due to a conformational
flexibility in that region. To describe the architecture of this site, I used structures from
ecNadE (PDB code: 1WXI) (Figure 4.12, 4.13) and bsNadE (PDB code: 1EE1) (Figure
4.14).
Sequence homology results also show that the residues responsible for Mg2+
binding are the most highly conserved (100% sequence identity) between the structural
homologs. BLAST results for spNadE show Mg2+ binding residues include: S56, D60,
E173, and T218 (T218 was not visible, as described above) (Figure 4.15, 4.16). (18).
The ATP binding sites between the spNadE-apo and ecNadE AMP-bound structure
(PDB code: 1WXI) do not show any significant cavity differences. When the bsNadE (PDB
code: 1EE1) was superposed on the structure it provided evidence that the conserved loop
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region closes off the ATP binding site and could play a role in the prevention of new ATP
molecules entering into the site (Figure 4.17). We assume that when NAD+ is released, the
site re-opens and allows for access of another ATP molecule.
NAAD BINDING SITE
According to previous studies on similar -NH3 dependent NadE homologs, NaAD
has been shown to bind across the dimeric chains in a cleft that is below the ATP binding
site (Figure 4.18) (20). This binding event should allow for the interaction of the phosphate of ATP with the carboxyl group of the pyridine ring of NaAD in order to allow
for the formation of the NaAD-adenylate intermediate. According to sequence homology,
residues responsible for the formation and stabilization of NaAD binding site in spNadE
include: L53- S56, D60, S61, V89-L91, F140, G143, N144, A147, R148, R150, T168,
E173, F178-K181, D184, T219, A220, L222, and A234 (Figure 4.19) (18). SpNadE
residues T219, A220, and L222 are not visible in the electron density. When compared to
bsNadE, NaAD binding site residues have approximately 85% residue identity.
In the surface representation comparisons between apo spNadE and, NaAD-bound,
bsNadE it was identified that the substrate binding pocket, for bsNadE, was visually, larger
than the predicted NaAD binding site for spNadE. Using Coot and PyMOL, we superposed
the structures and measured the distance between two residues that were directly across
from each other, on opposite sides of the binding pocket. These measurements were taken
across the centermost point of the pocket in an attempt to confirm an actual size difference.
More specifically, we, first, measured the distance between the  carbon of F128 and the 
sulfur of M253 of bsNadE. Then, we measured the distance between the  carbon of F139
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and  carbon K264 of spNadE. Results from these residue measurements identified that the
distance between F128 to M253 in (bsNadE) was 1.8 Å wider than the distance between
F139 and K264 (spNadE) (Figure 4.20). It was concluded that NaAD binding site is larger
when the substrate is bound.
Moreover, further analysis of the area shows that NaAD binding site expansion
seems to occur as an effect of the closure of the ATP binding site, after ATP is bound. This
occurrence is presumed to be similar to how the compression one end of a balloon causes
expansion of the opposite end. In contrast, ATP site expansion was identified when NaAD
is unbound. When NaAD is not bound, the structure reveals an open conformation of the
ATP binding site is and a more narrow conformation NaAD site, as described above
(Figure 4.21). This observation lead us to believe that the general mechanism for NAD+
biosynthesis is an ordered-sequential reaction (21) (Figure 4.22). We believe that the ATP
binding event occurs first, then the loop structure of the active site clamps down, which
promotes the open conformation of the NaAD site for acceptance of the substrate (Figure
4.21). More kinetic and structural studies will need to be done to confirm this occurrence.
NH3 CHANNEL
NAD+ biosynthesis can also occur through the utilization of glutamine as an -NH3
donor, for nucleophilic attack, to convert the NaAD-adenylate intermediate into NAD+.
This mechanism is most common in Mycobacterium tuberculosis (M. tuberculosis), Homo
sapiens, and Saccharomyces cerevisiae (4). MtNadE has been identified to have the ability
to utilize -NH3 and glutamine to make NAD+ (4, 22).
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The mtNadE (PDB code: 3SYT) structure is a large (600 kDa) octomeric biological
assembly structure with general characteristics similar to a cross, with a hollow, center
cavity (9). At the apex of each corner of the cross resides the C-terminal NAD+ synthetase
domain (9). This domain is a structural homolog of spNadE (RMSD of 1.6 Å) (Figure
4.23). Beneath the synthease resides glutaminase, an N-terminal amidotransferase, region
that that promotes the loss of –NH3 necessary for the NAD+ synthetase reaction (Figure
4.24) (9). From work conducted by LaRonde-LeBlanc et al., it was identified that
glutamine enters through a “tunnel system” in which ends at a Glu-Lys-Cys triad that is
proposed to promote the loss of -NH3 from the  carbon of glutamine (Figure 4.25) (9).
Once -NH3 is released it passes into a second “tunnel system” to initiate the nucleophilic
attack on the NaAD adenylate intermediate, as described previously. The entire occurrence
is proposed to travel approximately 73 Å before the reaction is complete (Figure 4.26,
4.27). Kcat for this reaction was 0.68 and Kcat/Km was defined at 0.4 s-1 mM-1 (9).
Structural homology studies have lead us to conclude that the direction of
nucleophilic attack comes from underneath the spNadE structure through channels formed
at the interface of the A and B chains (Figure 4.28). The residues that make up this interface
are made up of loop structures and include: Q18, L19, G167, T168, D169, N174, F179,
T180, K181, F182, G183, D184, G185, G186, A187, D188, F193, R270, H271, L272,
P273, and I274. This area is not highly conserved, and contains few hydrophobic residues.
This observation could provide reasoning for ease of access to shared NAD+ binding site
residues within this region. We infer, from this result, that passage of -NH3 in spNadE will
occur at the same entrance point that the tunnel system affords for mtNadE synthetase
region. Further tests will need to be conducted to confirm this assumption.
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4.3 MATERIALS AND METHODS
PROTEIN PRODUCTION AND CRYSTALLIZATION:
The methods used for protein production and crystallization were the same as those
described in Chapter 2, pages 27-30.
DYNAMIC LIGHT SCATTERING:
The methods used for Dynamic Light Scattering are outlined in Chapter 2, page 30.
THERMAL STABILITY TESTS:
The methods used for Thermal Stability test are outlined in Chapter 2, page 30-31.
Small molecule stability screening tests were done utilizing the strategy outlined in Chapter
3, page 64.
NADE KINETIC ASSAY
NadE activity was conducted at 1 mL, using a quartz cuvette. Activity reaction
solution concentrations are as follows: 60 mM HEPES (pH 7.5), 2 mM NaAD, 2 mM ATP,
10 mM ammonium chloride, 10 mM MgCl2, and 20 mM KCl, 0.5 µg of NadE, 1% ethanol
and 1 µg of alcohol dehydrogenase (ADH; Sigma-Aldrich St. Louis, MO) (protocol was
adapted from Nessi et al.) (11). ADH was necessary to confirm NAD+ formation through
its ability to promote a hydride shift to form NADH. NADH formation was detected by
UV at 340 nm. Reactions were measured at 340 nm for 5 minutes. Kinetic experiments
were prepared with increasing amounts of one substrate while keeping the other substrate
at activity reaction concentrations. ATP kinetic experiments concentrations are as follows:
0.5 mM, 1 mM, 2 mM, 4 mM, 6 mM, 8 mM, 10 mM, and 12 mM. NaAD kinetic experiment
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concentrations are as follows: 0.125 mM, 0.250 mM, 0.500 mM, 1 mM, 1.5 µM, 2 mM,
and 2.5 mM. Reactions were conducted using the Nanodrop 2000c UV spectrometer.
DATA COLLECTION AND DATA PROCESSING
Prior to data collection NadEsulf crystal was transferred to the solution of cryoprotectant composed of 10 % glycerol, 5% w/v PEG 3350, and 0.1 M ammonium sulfate.
The NadE-apo crystal was cryo-cooled by direct transfer from the drop to liquid nitrogen.
Diffraction data were collected at the Advanced Photon Source at Argonne National
Laboratory in Lemont, IL. The data from NadE-apo crystal was collected at 19 ID of the
Structural Biology Center Collaborative Access Team (SBC-CAT) and data from the
NadEsulf crystal was collected at 21 ID-G at the Life Sciences Collaborative Access Team
(LS-CAT). Diffraction experiments were performed at 100 K. Data processing was
performed with HKL-2000 and the details on the diffraction experiments and collection
statistics are summarized in Table 4.2.
STRUCTURE DETERMINATION, REFINEMENT AND VALIDATION
HKL-3000 in combination with MOLREP were used for structure determination.
Both of the NadE structures were solved by molecular replacement. The structure of
NadEsulf was solved first using as the starting model the NAD+ synthetase Salmonella
typhimurium (PDB code: 3HMQ; 67% of sequence identity). The structure of NadEsulf was
used as a starting model for determination of NadE-apo structure. Both structures were
refined with HKL-3000 and Refmac. Coot was used for model building and adjustment, as
well as for structure validation. The final validation was performed with Molprobity and
CheckMyMetal. Both structures together with structure factors were deposited to the
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Protein Data Bank under the accession codes 5HUJ and 5HUH for NadE-apo and NadEsulf,
respectively. Information on model refinement and validation was summarized in Table
4.3.
OTHER COMPUTATIONAL METHODS
The other computational methods used are the same as were described in Chapter
2, page 33.
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4.4 TABLES AND FIGURES
Table 4.1: Kinetic results from spNadE experiments. These results are compared to results
reported in the literature for baNadE and bsNadE (2, 14).
Enzyme
spNadE
bsNadE
baNadE

Variable
Substrate
NaAD
ATP
NaAD
ATP
NaAD
ATP

Fixed
Substrate
ATP
NaAD
ATP
NaAD
ATP
NaAD

Km(app) (µM) Kcat (s-1)
375 ± 0.12
340 ± 0.03
152
289
179
196
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4.16
5.63
NR
NR
NR
NR

Kcat/Km
(s-1 mM-1)
11.09
16.55
NR
NR
NR
NR

Table 4.2: Summary of NadE and NadEsulf data collection and processing.
Protein

NadEsulf

NadE-apo

PDB accession code

5HUH

5HUJ

Diffraction source

APS (21 ID)

APS (19 ID)

Wavelength (Å)

1.000

0.979

Detector

MX300HS

ADSC Q315r

Crystal-to-detector distance (mm)

300

300

Rotation range per image (°)

1

1

Total rotation range (°)

200

200

Exposure time per image (s)

1

1

Space group

P 21 21 21

P 21 21 21

a, b, c (Å)

σ Cutoff

49.521
92.104 49.786
92.964
128.569
128.355
50.00- 2.50 (2.54- 39.37- 2.10 (2.142.50)
2.10)
-3 
-3 

Total No. of reflections

19874 (856)

32708 (1586)

Completeness (%)

92.6 (82.9)

91.8 (90.5)

Redundancy

6.6 (5.3)

5.6 (5.0)

〈 I/σ(I)〉

7.5 (2.4)

11.9 (2.3)

Rr.i.m.

0.159 (0.588)

0.156 (0.862)

Rp.i.m.

0.060 (0.238)

0.064 (0.373)

Resolution range (Å)

Overall B factor from Wilson plot 26.8
(Å2)
CC ½
(0.873)
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29.6
(0.645)

Table 4.3. Summary of spNadE and spNadEsulf structure refinement statistics
Protein

NadEsulf

NadE-apo

Resolution range (Å)

43.72-2.50 (2.56-2.50)

39.37- 2.10 (2.15-2.10)

Completeness (%)

93.10 (92.1)

91.66 (89.5)

 Cut-off

0

0

No. of reflections, working 18796
set
No. of reflections, test set 1338

31023

Final Rcryst

0.171 (0.222)

0.168 (0.205)

Final Rfree

0.225 (0.279)

0.212 (0.282)

No. of non-H atoms

4301

4291

Protein

4025

4025

Ligand

27

1

Solvent

249

265

Bonds (Å)

0.012

0.016

Angles (°)

1.4

1.6

Protein

32

29

Ligand

74

38

Most favored (%)

98.8

99.2

Allowed (%)

99.8

99.6

Chain A

9-215, 228- 282

9-97, 99-215, 228- 282

Chain B

9-215, 228- 282

9-97, 99-215, 228- 282

1630

R.m.s deviations

Average B factors (Å2)

Ramachandran plot

Visible Residues
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Figure 4.1: Schematic of general spNadE reaction. This diagram shows the general
mechanism of an NH3-dependent synthetase.
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Figure 4.2: SpNadE DSF result. Chart depicts differential scanning fluorimetry results for
NadE; results show that NadE has a greater thermal stability in acidic conditions.
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Figure 4.3: SpNadE crystallization results. The image on the left shows a picture of the
needle-like cluster of spNadE crystals. The right image shows the rectangular, plate-like
crystals found underneath the needle clusters that were optimal for diffraction.
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Figure 4.4: SpNadE sequence alignment. This image show sequence alignment results for
spNadE and its homologs originating from Salmonella typhimurium (stNadE), Eschericia
coli (ecNadE), Bacillus anthracis (baNadE), Vibrio choloera (vcNadE), Pseudomonas
aeruginosa (paNadE), Bortadella pertussis (btNadE), Fracisella tulerensis (ftNadD),
Camphylobacter jejuni (cjNadE), and Helicobacte r pylori (hpNadE)
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Figure 4.5: Sequence alignment of spNadE and hsNadE. This alignment result shows low
sequence identity and similiarity between the bacterial and human protein. The sequence
of the C-terminal glutaminase domain of hsNadE was omited.
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Figure 4.6: Cartoon representation of spNadEsulf. This is a cartoon representation of
spNadEsulf in various orientations bound to sulfate and Mg2+ (green spheres).
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Figure 4.7: Cartoon representation of apo spNadE. This is a cartoon representation of the
apo form of spNadE in various orientations. The sphere highlighted in green represents Cl.
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Figure 4.8: The spNadE monomer. Cartoon representation of spNadE monomer at various
orientations. Alpha helices are colored in cyan, beta-strands are colored red, and loop
regions are colored magenta.
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Figure 4.9: SpNadE monomer with marked missing residues. Cartoon representation of
spNadE monomer shown at two different orientations. Missing residues on this structure
include residues 97 and 216-227. The missing region from E215-L228 is highlighted in red
to indicate that this region is highly conserved and will be described in greater detail in
later figures. Alpha helices are colored in cyan, beta-strands are colored red, and loop
regions are colored magenta. The N and C termini are both labeled on the structure on the
right.
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Figure 4.10: Cartoon representation of conserved regions of spNadE. Cartoon and surface
representations of the spNadE dimer in various orientations. The dark blue color shows
regions of structure that are highly conserved. Areas in red are the least conserved.
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Figure 4.11: SpNadE and proposed active site. Cartoon representation of spNadE with
superposed, conserved loop region (K225-L231) from bsNadE (PDB code: 1EE1).
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Figure 4.12: Proposed spNadE ATP binding site. Cartoon representation of spNadE
superposed with ecNadE (salmon) (PDB code: 1WXI) to show probable location of ATP
binding site without the conserved loop. AMP is bound to ecNadE.
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Figure 4.13: Proposed ATP binding pocket. Cartoon representation of spNadE and ecNadE
(salmon) (PDB code: 1WXI) to show probable location of ATP binding site without the
conserved loop. AMP is bound to ecNadE and the green spheres are two Mg2+ molecules.
The AMP molecule bound in lower right quadrant of the ecNadE molecule may give
insight into the directionality of NaAD binding within the site.
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Figure 4.14: SpNadE modeled with active site loop. Surface representation of spNadE with
a superposed loop from bsNadE. Areas highlighted in red represent conserved regions for
the ATP and NaAD binding sites. Images to the far right are meant to display conserved
residues of the loop that interact with the site without (top) and with (bottom) substrate.
ATP identified in this figure is also superposed from the bsNadE (PDB code: 1EE1)
structure.
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Figure 4.15: Highly conserved spNadE Mg2+ binding site. The superposition of Mg2+
binding site residues for spNadE apo structure (blue) and spNadEsulf (yellow).
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Figure 4.16: Conserved Mg2+ binding site superposed with equivalent fragment of ecNadE.
The superposition of Mg2+ binding site residues for spNadE apo structure (yellow) and
ecNadE (PDB code: 1WXI; salmon).
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Figure 4.17: Surface representation of ATP binding site with and without the active site
loop. The image to the left (yellow) is spNadE, the middle image (salmon) is ecNadE (PDB
code: 1WXI), the right figure is the bsNadE (PDB code: 1EE1). For the bsNadE figure the
area highlighted in red represents the conserved loop region that, essentially, closes off the
binding site upon binding of ATP.
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Figure 4.18: Proposed spNadE NaAD binding site. Cartoon and surface representation of
proposed the spNadE NaAD binding site of NaAD from superposed bsNadE structure
(PDB code: 2NSY). Notice the binding of NaAD across the interface of the dimer.
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Figure 4.19: Proposed spNadE residues for NadE binding. Cartoon representation of
superposed spNadE (yellow) and bsNadE (cyan) (PDB code: 2NSY) NaAD binding site
residues.
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Figure 4.20: SpNadE NaAD binding site size comparison. The comparison of spNadE
(yellow) and bsNadE (green) (PDB code: 2NSY: RMSD 0.85 Å) NaAD binding site
residues. Distances are measured from the  carbon of F128 to the  sulfur of M253
(bsNadE) and the  carbon of F139 to the  carbon of K264. Structure comparisons
indicate that when NaAD is bound the site is approximately 2.0 Å wider than when it is
unbound.
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Figure 4.21: SpNadE ATP active site comparison. Cartoon representation spNadE and
bsNadE (cyan) (PDB code: 2NSY) with boxes showing how open the ATP binding site is
when no substrate is bound. This observation lead to the assumption that ATP binds first
in the formation of NAD+, then the NaAD site opens after ATP binding (details shown in
next figure).
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Figure 4.22: Cleland diagram of proposed general mechanism for spNadE. Schematic of a
proposed ordered-sequential mechanism of enzymatic activity for spNadE from structural
studies (20).
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Figure 4.23: Comparison of spNade and mtNadE. Cartoon representation of the octameric,
glutamine-dependent NAD+ synthetase from M. tuberculosis (PDB code: 3SYT). On the
left SpNadE (yellow) has been superposed on this structure to show its similarity to the
NH3 synthetase region of mtNadE. On the right, spNadE is colored by chain and this color
schema is used in the following figures.
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Figure 4.24: The glutamine and NH3 channel for mtNadE. Surface representation showing
superposition of of mtNadE (PDB code: 3SYT, grey) and spNadE (yellow and blue). This
image provides a generalized diagram of the direction of the “tunnel system”. The system
is composed of two tunnels: the first binds Gln at the Glutaminase/ amidotransferase region
and promotes the removal of NH3, the second transfers NH3 to the synthetase region for
NAD+ biosynthesis (9). Total length of the tunnel is approximately 73 Å (9).
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Figure 4.25: Schematic of the the NH3 tunnel of mtNadE. The diagram adapted from
LeRonde-LeBlanc et al. shows a general mechanism for NAD+ biosynthesis in glutaminedependent NAD+ synthetases (9).
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Figure 4.26: The proposed NaAD binding site in the mtNadE synthetase domain. SpNadE
(yellow and blue) is superposed on mtNadE (PDB code: 3SYT; grey). NaAD is shown in
stick representation. NaAD in spNadE was modeled using the mtNadE structure.

123

Figure 4.27: The discovery of the possible direction of NH3 entrance in spNadE. Surface
representation of spNadE superposed on mtNadE (PDB code: 3SYT) to show the proposed
direction of travel of NH3 from the glutaminase/ amidotransferase region to the NAD+
synthetase region. The yellow/blue structure to the far right removes the superposed
mtNadE structure to show evidence of two openings at the dimer interface of NadE that
may provide insight into the direction of nucleophilic attack on the NaAD-adenylate
intermediate that would be directly behind that interface during NAD+ biosynthesis.
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Figure 4.28: The proposed NH3 passageway. Cartoon (left) and surface representations
(right) of spNadE and NaAD molecules superposed from mtNadE (PDB code: 3SYT). The
NaAD substrates are located behind the NH3 passageway (highlighted in pink). Cavities,
indicated by the circles, could explain the direction of nucleophilic attack of NH3. We
presume that NH3 enters through one of these cavities in order to promote the conversion
of NaAD to NAD+.
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CHAPTER 5
THE STRUCTURAL CHARACTERIZATION OF SAGB, SAGC, SAGD AND SAGG PROTEINS
FROM STREPTOCOCCUS PYOGENES

5.1 INTRODUCTION
In GAS the proposed SagBCD complex, composed of proteins expressed from the
sag operon: SagB, SagC, and SagD, is considered to be primarily responsible for the
biosynthesis of SLS (1, 2). More specifically, as suggested by Molloy et al., the expression
of the sagA reading frame, of the sag operon, results in the translation of a 53 amino acid
strand (SagA). The strand is then converted into Streptolysin S (SLS) by the activity of the
SagBCD. As determined through sequence homology studies, the SagA strand is divided
into two segments: the leader peptide segment (residues M1-G23) and the protoxin
segment (residues C24-T53). The leader segment contains an FXXXB motif (F4-I8:
FTSNI) that is considered to be a recognition sequence for truncation of the strand by SagE
(1, 3) (Figure 5.1). The mechanism for this truncation event has yet to be confirmed, but is
presumed to be one of two events that is necessary in the conversion of SagA into SLS (1,
2). The second event involves the modification of cysteine, serine, and threonine residues
within the protoxin segment (2). The chemical mechanism for this event is also undefined.
The protoxin sequence (…↓CCCCCTTCCFSIATGSGNSQGGSGSYT) is considered to
continue thru biosynthetic modification by action of SagBCD (Figure 5.2). Within the
complex, SagC, a cyclodehydratase, is considered to act first in the conversion of the
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cysteine, serine, and threonine residues into thiozole, oxazole, and metyloxazole rings,
respectively (2). SagB is a proposed dehydrogenase, using flavin mononucleotide (FMN)
as a cofactor, and is responsible for double-bond formation, within the rings (Figure 5.2).
This step is considered the “finishing step” in the conversion of SagA into SLS. SagD is
considered to be the docking protein that keeps the complex together to allow for SLS
biosynthesis (1, 2) Sequence homology studies have identified the possibility of ATP being
required for the activity of SagD (4). This interaction has yet to be confirmed.
Research interests also lie in the determination of the structure and function of
SagG. SagG is a membrane associated protein proposed to play a role in the formation of
the, membrane-bound, ATP-binding cassette. This cassette is considered responsible for
the release of SLS into the extracellular environment (1, 2).
Currently the Protein Data Bank (PDB) contains no other structures with significant
sequence similarity (over the entire sequence) to SagB, SagC, SagD, or SagG (Refer to
Chapter 1, Table 1.2)
This chapter will provide a description of production of SagB, SagC, SagD and
SagG proteins, as well as approaches used in an attempt to obtain their crystals.
5.2 RESULTS AND DISCUSSION
PROTEIN PRODUCTION
SagB-D plasmid construction, protein expression, and purification protocols were
the same as described for QSEs (Chapter 2, pages 27-30). In contrast to QSE isolation
results, isolation attempts produced only microgram quantities of soluble protein, per liter
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of culture (Figures 5.3- 5.5). SagD gel filtration results provided evidence of possible dimer
formation, when compared to peaks from protein standards (results not shown). With the
assistance of an undergraduate volunteer, David Mysona, we were able to isolate, at least,
5 mg of SagG per liter for culture (Figure 5.6). Additionally, SagG was found to be unstable
in the imidazole-containing elution buffers, so immediate dialysis was required upon
elution. Attempts to modify the growth conditions by changing IPTG concentrations,
growing cultures in minimal media, decreasing inoculation temperature, and overexpression of the protein in different cell lines were used in attempts to improve folding
and stability. None of the attempts were successful at improving protein yield in any of the
Sag proteins.
Attempts were also made to isolate homologous proteins from different bacteria
and different GAS strains. Work was initiated for the overexpression of the bacteriocin
biosynthesis cyclodehydratase protein from Staphylococcus aureus in BL21 (DE3) E. coli.
This protein is a structural homolog of SagC is predicted to be a more stable protein
construct for crystallization (5). To date, attempts to isolate this protein have been
unsuccessful.
A SagD analog was, also, identified from the M6 strain from GAS from the
DNASU plasmid repository (Tempe, AZ). This construct is referred to as
“SagD_DNASU”. The plasmid is designed to express for Kanamycin-resistance and a 6x,
C-terminal, polyhisitidine tag. There is a variation in molecular weight between SagD, at
51 kDa, and SagD_DNASU, at 45 kDa. More specifically this difference is due to a 50
amino acid truncation at the N-terminus of the sequence and a 48 residue extension at the
C-terminus (residues 346-394) of SagD_DNASU. In addition, the protein from DNASU
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carries a tyrosine mutation at residue 124 (Figure 5.6). Isolation attempts produced
approximately 24 mg of protein per liter of culture, (after dialysis). Unfortunately, as
determined from gel filtration results, a large percentage (~90%) of the isolated product
was considered aggregate protein. A non-aggregated fraction (not shown) that was
confirmed to contain SagD_DNASU and was screened for crystal formation, but no
crystals have been obtained to date.
Refolding attempts on all of the Sag proteins were conducted and provided
marginal success. The refolding conditions were partially based on Thermo Scientific
Pierce® Protein Refolding Kit, and the conditions are listed in Table 5.1 (14). The most
optimal conditions for refolding, for SagB, were solutions 2 and 3. For SagC, no
precipitation was observed in solution 9, and for SagD solutions: 1, 2, 3, 4, 6, 8, 14, 15
were most optimal for refolding. Unfortunately, when gel filtration/ size exclusion
chromatography was conducted, the peaks were presumed to be evidence of non-specific
aggregation.
SagG was most stable in refolding condition 12. After the elution from the Ni-NTA
column the protein was approximately 85-90% pure. As a result, the protein was further
purified using gel filtration. The refolding of SagG proved to be only moderately successful
as we were able to isolated only ~1 mg of pure protein from an, initial, 1L culture.
CRYSTALLIZATION
Due to protein aggregation and low protein yields only, approximately, 1000
combined crystal screening experiments were conducted for SagB-G.
MOLECULAR CLONING OF SAGBCD

132

The marginally successful attempts at SagB, SagC and SagD isolation prompted us
to develop a methodology for expression of the entire SagBCD complex. Our approach
was based on the strategy presented by Markley et al. (2012) (6). For the co-expression of
the Sag proteins we enacted two slightly different approaches. Results for Strategy 1,
SagBCD co-expression using two plasmids, showed that SagB was successfully introduced
into the pETDuet™ (Novagen, Madison, WI) plasmid and it has been confirmed through
sequencing (Figure 5.8). There were numerous attempts, to insert SagD into the second
multi-cloning site, in the plasmid, but attempts have been unsuccessful. However there was
success with the addition of new restriction sites to the SagD insert (Figure 5.9). Results
for Strategy 2, SagBCD expression from 3 individual plasmids, showed some success as
evidenced

by

growth

of

transformed

BL21

(DE3)

E.

coli

on

the

Ampicillin/Kanamycin/Chloramphenicol infused LB agarose plates. The introduction of
each of the individual plasmids still needs to be confirmed through sequencing (refer to
Figure 5.10 for agarose gel results). Culture and over-expression of the proteins showed
evidence of protein production (not shown) although the product was completely insoluble.
HOMOLOGY MODELING
We used PHYRE2 for homology modeling and the approach described in the
homology modeling section in Chapter 3, page 60. Collectively, structure confidence
parameters for top homology models was greater than ≥99 %, but sequence identity for
models ranged from 10- 41%. The homology models, with quality parameters of 100%
confidence, included templates from: Thermotoga maritima (PDB code: 4EO3; sequence
identity: 18%; 69% sequence coverage) for SagB,(Figure 5.11), Escherichia coli (PDB
code: 3H9G; sequence identity: 10%; 91% sequence coverage) for SagC (Figure 5.12 ),
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Prochloron sp. 06037A (PDB code: 4BS9; sequence identity 23%; 79% sequence
coverage) for SagD (Figure 5.13), and Thermotoga maritima (PDB code: 4YER; sequence
identity 41%; 74% sequence coverage) for SagG (Figure 5.14). The results of the homology
modeling suggest that SagG, SagB, SagC and SagD proteins most likely dimerize.
Therefore, one may speculate that the enzymatic complex responsible for SLS formation
has composition (SagB)2(SagC)2(SagD)2 and not SagBCD as reported in the literature.
FUTURE DIRECTIONS
In order to increase the likelihood of Sag protein isolation and overcome issues with
solubility new strategies must continue to be initiated.

New approaches include:

introducing substrates (i.e. ATP and/or SagA) into the culture media during growth and
over-expression. The assumption is that through substrate interaction the proteins can be
stabilized and could allow for higher yields of soluble during isolation. SagD was identified
to be a similar to proteins that are a part of the YcaO family of proteins which are
considered responsible for the formation of thiazole and oxazole modifications in bacteria;
they are proposed to require ATP for activity (4, 7).
To improve protein yield utilizing conditions that can slow the rate of protein overexpression could be conducive to improving solubility. Possible avenues of approach could
be the growth of the transformed bacteria in minimal media and/or the use of Arctic
Express Cells (Agilent Technologies, Santa Clara, CA) which contain chaperones proteins
that can allow for folding at temperaturs ranging between 10- 13 °C.
Another strategy involves protein engineering and the addition of maltose-binding
protein (MBP) to the N or C-terminus of each of the Sag proteins. Maltose binding proteins
has been shown to improve solubility of unstable proteins, when attached (8). Deletions
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of predicted unstructured fragments and/ or a change of the His-tag location may also be
useful approaches. (9, 10, 11)
While the expression of all three of the proposed SagBCD complex proteins have
been completed, in one cell, continued work will need to be done to improve yield of the
complex proteins in order to visualize interactions, if any, through x-ray crystallography.
Continued work will also be done to attempt to introduce SagD into the pET-Duet plasmid
that contains SagB. Introduction of new restriction sites have been completed for SagD
(Figure 5.7), but a more optimized strategy for ligation needs to be prepared to successfully
insert the SagD into pET-Duet+SagB for co-expression. Strategies to overcome this could
include the use of temperature-cycle ligation strategy created by Lund et al. (12).
5.3 MATERIALS AND METHODS
PROTEIN PRODUCTION AND CRYSTALLIZATION
All experiments for transformation, overexpression, isolation and crystallization
utilized the strategies outlined in Chapter 1, pages 27-30.
PROTEIN REFOLDING AND ISOLATION
After initial attempts at isolation proved unsuccessful at producing a significant
amount of protein for crystal screening. The a small portion of the insoluble fraction (~10
mg) was dissolved in 6 M Guanidine HCl or 8 M Urea and each of the Sag proteins were
re-isolated by IMAC in denaturing conditions.
After elution of the unfolded protein from the column, approximately 100 µL of
eluate, in denaturing conditions, was added to 10 mL of the re-folding conditions reported
in Table 5.1. This approach is called fast dilution re-folding and was reported to be
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successful for some proteins (13, 14). After the dilution the solution of the protein was
stirred overnight (~12 hrs) at room temperature. The refolding condition that produced the
least of protein precipitate were selected for further experiments. The solution(s) identified
during these experiments were used to store the protein and perform gel filtration
purification. After gel filtration, the protein was checked for purity using SDS-PAGE,
concentrated and used for crystallization experiments.
MOLECULAR CLONING OF SAGBCD COMPLEX
Due to the instability of the Sag proteins, it was assumed that through co-expression
of the proteins, there could be an increase in the stability of the individual proteins as a
result of possible stabilizing interactions from complex formation. To accomplish this, two
strategies were enacted; in Strategy 1 the goal was to introduce sagB, sagD into a single
plasmids and allow it to be co-expressed with sagC. More specifically, one of the plasmids
would be engineered to co-express SagB and SagD in a plasmid encoding for Ampicillinresistance (the pETDuet™ plasmid), while SagC would be expressed on a separate plasmid
encoded to promote Kanamycin resistance (Figure 5.15). In Strategy 2, the intention would
be to co-express each plasmid individually, within the same organism. Each plasmid would
contain genetic information for different antibiotic resistance, more specifically, SagB
would be introduced into a plasmid encoding for Ampicillin-resistance, SagC into a
plasmid encoding for Kanamycin-resistance, and SagD into a plasmid encoding for
Chloramphenicol resistance (Figure 5.16).
These protocols were adapted from published strategies from Tolia and Joshua-Tor
(2006) and Markley et al. (2011) and are explained in greater detail below (6, 15).
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Strategy 1:
Plasmids for SagB, SagD, and pET-DUET (Novagen, Madison, WI) were
transformed into competent DH5 alpha cells (NEB, Ipswich, MA) using the heat/ cold
shock technique (16). A single colony from each transformation experiment was cultured
in 5 mL of LB media, with respective antibiotic, for 12-16 hours. Each culture was
centrifuged to at 3900 g for 10 min and the culture media was discarded. Plasmids were
extracted and concentrated according to the protocol for the GeneJET plasmid Miniprep
kit (Thermo Scientific, Waltman, MA). Plasmid concentrations were determined by UV
spectroscopy, and eventually stored at -20 ºC for future testing.
For the introduction of SagB into the pETDuet™ plasmid, restriction enzymes NdeI
and XhoI were identified for excision and experiments were conducted in accordance with
protocol from NEB Double digest finder (17). At experiment completion, agarose gel
electrophoresis was used to isolate cut pETDuet™plasmid and excised SagB. Upon
identification of SagB and pETDuet™, they were cut out of the gel and made soluble
through the use of the Plasmid GeneJET Gel extraction Kit (Thermo Scientific, Waltman
MA). Ligation experiments were prepared in 6, 20 µL experiments. Experiment conditions
all contained a standard, 2 µL of SagB DNA, 2 µL of buffer, and 1 µL of T4 DNA Ligase
(NEB). Variation in the experiment preparation occurred with increasing volumes of
plasmid DNA in the following consecutive volumes, 0.5 µL, 1 µL, 1.5 µL, 2 µL, 2.5 µL,
and 3 µL, with accommodating amounts of nuclease-free water to achieve a 20 µL total
volume. Ligation experiments were run overnight at 18 °C. Due to low recovery from the
gel ligation, experiments went directly to the transformation protocol. Any colony growth
that was obtained was cultured and confirmed by sequencing.
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SagD, within the pjexpress411 plasmid (DNA 2.0, Menlo Park CA), did not contain
useful restriction sites for introduction into the pETDuet™system, so new restriction sites
had to be created. Primers for restriction sites EcoRI and NdeI created and were introduced
by PCR using the following protocol: Cycle # 1: 98 °C: 2 min, Cycle # 2-33: Denature- 98
°C, Anneal-65 °C- 55 °C: 30 sec, Extend-72 °C:1 min, 30 sec, Final Cycle (# 34):
Denature-98 °C, Anneal-65 °C, Extend 72 °C, 5 min, Final Hold at 4 °C.

Primer

information is shown in Figure 5.17.
Strategy 2:
In strategy 2, SagB (Ampicillin-resistant) and SagC (Kanamycin-resistant)
plasmids were introduced into BL21 (DE3) cells, simultaneously, using the heat shock/
cold shock method (16). Cells were cultured and grown on Amp/Kan resistant plates for
confirmation. SagBC cells were then made competent using a calcium chloride method
adapted from Sambrook et al. (18). SagD, which has Kanamycin resistance in the pJexpress
plasmid, had to be transplanted into another antibiotic-resistant plasmid to confirm
successful transformation into the new SagBC strain. The SagD insert was cut from the
pJexpress41 plasmid (DNA 2.0, Menlo Park, CA) using the restriction enzymes XhoI and
XbaI and transferred into a pHSG396 plasmid which contained genomic information for
Chloramphenicol resistance. The transfer of the insert was conducted utilizing the same
techniques outlined in Strategy 1. The introduction of SagD insertion into the Cam-res
plasmid was confirmed by sequencing (Eton Biosciences, RTP, NC). The plasmid was
introduced into the SagB/C competent cells, and introduction was confirmed by the growth
of the bacteria on the Kan/Amp/Cam resistant plates.

138

OTHER COMPUTATIONAL METHODS
All Other Computational Methods are consistent with what was described in
Chapter 2, page 33.
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5.4 TABLES AND FIGURES
Table 5.1: Conditions used for protein re-folding (14).
Condition Components
1

0.5 M L-arginine, 0.05 M MES (pH 6.0), 0.05 M NaCl, 0.05 M KCl

2

0.5 M L-arginine, 0.05 M Tris (pH 8.0), 0.05 M NaCl, 0.05 M KCl

3

0.5 M L-arginine (pH 8.5)

4

0.5 M guanidine HCl, 0.05 M MES (pH 6.0)

5

0.5 M guanidine HCl,0.05 M Tris (pH 8.0)

6

0.25 M KCl, 0.05 M HEPES (pH 6.0)

7

0.4 M sucrose, 0.05 M MES (pH 6.0)

8

0.4 M sucrose, 0.05 M Tris (pH 8.0)

9

1% w/v PEG 3350, 0.05 HEPES (pH 7.5), 0.01 M NaCl, 0.01 M KCl

10

1% w/v beta-cyclodextrin, 0.05 HEPES (pH 7.5), 0.01 M NaCl, 0.01 M KCl

11

0.5 M glycine ethyl ester HCl, 0.05 HEPES (pH 8.0), 0.01 M NaCl, 0.01 M

12
13

0.5 M NDSB-221, 0.05 HEPES (pH 8.0), 0.01 M NaCl, 0.01 M KCl
KCl
0.5 M NDSB-221, 0.05 HEPES (pH 8.0), 0.01 M NaCl, 0.01 M KCl

14

0.5 M L-arginine (pH 8.5) , 0.01 M MgCl2, 0.01 M KCl

15

0.5 M L-arginine (pH 8.5), 0.01 M CaCl2, 0.01 M KCl

16

0.5 M L-arginine (pH 8.5), 0.001 M EDTA, 0.01 M KCl
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Figure 5.1: Overview of predicted SagBCD complex reaction. a schematic of the proposed
activity of the proteins of the SagBCD complex (3). The FxxxB region of SagA is described
as a possible recognition sequence by SagE (1). The FxxxB corresponds to phenylalanine
followed by 3 residues and a basic amino acid residue B (3).

141

Figure 5.2: Schema of the proposed enzymatic activity of SagB and SagC. A schematic of
the proposed activity of SagB and SagC (3). SagC is considered to operate as a
cyclodehydratase forming the ring (3). SagB is suggested to function as a dehydrogenase,
removing hydrogen from the ring with the assistance of flavin mononucleotie (FMN) to
create reduced FMN (FMNH2) (3).
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Figure 5.3: SagB SDS-PAGE isolation result. This image shows SDS-PAGE results
confirming the isolation of SagB. Total volume obtained: ~ 1 mg/ mL. Sample volume
applied to well: 10 µL. The molecular weights for marker poteins are reported in kDa.
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Figure 5.4: SagC SDS-PAGE isolation result. SDS-PAGE results confirming the isolation
of SagC. Total volume obtained: ~ 1 mg/ mL. Sample volume applied to well: 10 µL.
Isolated SagC is marked with an asterisk. The molecular weights for marker poteins are
reported in kDa.
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Figure 5.5: SagD SDS-PAGE isolation result. SDS-PAGE results confirming the
isolation of SagD. Total volume obtained: 1 mL. Concentration: ~1 mg/mL. Sample
volume applied to well: 10 µL. The molecular weights for marker poteins are reported in
kDa.
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Figure 5.6: SagG SDS-PAGE isolation result. SDS-PAGE results confirming the
isolation of SagG. Total volume obtained: 1 mL. Concentration: ~5 mg/mL. Sample
volume applied to well: 10 µL. The molecular weights for marker poteins are reported in
kDa.
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Figure 5.7: SagD/SagD_DNASU sequence alignment results. Comparison of SagD
(SagD_DNA_2.0) and SagD_DNASU sequences.
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Figure 5.8: Agarose gel result for SagB and pETDuet™ restriction enzyme experiments
(Strategy 1). This agarose gel result shows evidence of restriction enzyme activity on the
pJexpress411 plasmid containing SagB plasmid, and the pETDuet™ plasmid. “SagB (cut)”
was successfully ligated into the pETDuet™ plasmid.
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Figure 5.9: Agarose gel result for addition of new restriction sites for SagD (Strategy 1).
The agarose gel shows evidence of amplification and isolation of the SagD insert with new
EcoRI and NcoI restriction sites.
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Figure 5.10: Agarose gel result for the SagD and pHSG396 restriction enzyme experiment
(Strategy 2). The agarose gel presents the successful removal of the SagD insert from the
pJexpress411 plasmid, as well as, results of the successful excision of the pHSG396
plasmid. The SagD insert was successfully transferred into the pHSG396 plasmid.
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Figure 5.11: Homology modeling result for SagB. Calculated structure of SagB obtained
from using PHYRE2. The homology modeling results indicate that SagB may form a
dimer. The putative dimer is represented in cartoon and surface representations. The
sequence conservation is mapped on the protein surface representation (blue color
corresponds to highly conserved residues, while red indicates variable residues). Binding
sites for FMN (yellow) are highly conserved in term of protein sequence. The structure is
based on bacterioferritin comigratory protein from Thermotoga maritima (PDB code:
4EO3).
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Figure 5.12: Homology modeling result for SagC. Calculated structure of SagC was
obtained using PHYRE2. The modeling results also suggests that SagC may form a dimer.
The putative dimer is represented in cartoon and surface representations. The sequence
conservation is mapped on the protein surface representation (blue color corresponds to
highly conserved residues, while red indicates variable residues). The structure is based on
a complex between E. coli MccB protein and MccA-N7isoASN peptide (PDB code:
3H9G). The peptide (pale green) is a microcin C7 analog.
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Figure 5.13: Homology modeling result for SagD. Calculated structure of SagD obtained
using PHYRE2. The structure is based on structure of heterocyclase TruD from an
uncultured Prochloron sp. 06037A (PDB code: 4BS9). Similar to the structures above, the
homology model suggests that SagD may also form a dimer. The putative dimer is
represented in cartoon and surface representations. The sequence conservation is mapped
on the protein surface (blue color corresponds to highly conserved residues, while red
indicates variable residues). AMP and Zn2+ (yellow-AMP / green-Zn2+) positions were also
modeled using the heterocyclase TruD structure.
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Figure 5.14: Homology modeling result for SagG. Calculated structure of SagG was
obtained using PHYRE2. The structure is based on a structure of the ABC transporter ATPbinding protein from Thermotoga maritima (PDB code: 4YER). The homology model
results predict that SagD is also a dimer with a proposed binding sites for ADP (pink). The
putative dimer is represented in cartoon and surface representations. The sequence
conservation is mapped on the protein surface representation (blue color corresponds to
highly conserved residues, while red indicates variable residues).
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Figure 5.15: Schematic of SagBCD molecular cloning strategy 1. This is a diagram of
Strategy 1 for SagBCD co-expression in E. coli. This strategy involves the insertion of two
plasmids (one expressing for SagB and D, and the other for SagC only) into BL21 (DE3)
E. coli for co-expression experiments. The experimental design was adapted from Markle
et al. (11).
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Figure 5.16: Schematic of SagBCD molecular cloning strategy 2. This diagram describes
Strategy 2 for SagBCD co-expression in E. coli. This strategy involves the insertion of
three individual plasmids (expressing specifically for SagB, SagC, and SagD) into BL21
(DE3) E. coli for co-expression experiments.
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Figure 5.17: Schematic of primer design used for restriction site modification of SagD
(Strategy 1). This diagram displays the strategy for introducing new restriction sites into
the SagD plasmid prior to insertion of SagD reading frame into pETDuet™. This is done
to ensure restriction site compatibility during ligation experiments.

157

5.5 REFERENCES
1. Molloy, Evelyn M., Paul D. Cotter, Colin Hill, Douglas A. Mitchell, and R. Paul
Ross. "Streptolysin S-like Virulence Factors: The Continuing SagA." Nature Reviews
Microbiology 9.9 (2011): 670-81. Print.
2. Lee, S. W., D. A. Mitchell, A. L. Markley, M. E. Hensler, D. Gonzalez, A. Wohlrab,
P. C. Dorrestein, V. Nizet, and J. E. Dixon. "Discovery of a Widely Distributed Toxin
Biosynthetic Gene Cluster." Proceedings of the National Academy of Sciences 105.15
(2008): 5879-884. Web
3. Mitchell, D. A., S. W. Lee, M. A. Pence, A. L. Markley, J. D. Limm, V. Nizet, and J.
E. Dixon. "Structural and Functional Dissection of the Heterocyclic Peptide
Cytotoxin Streptolysin S." Journal of Biological Chemistry 284.19 (2009): 130043012. Web.
4. Dunbar, Kyle L., Joel O. Melby, and Douglas A. Mitchell. "YcaO Domains Use ATP
to Activate Amide Backbones during Peptide Cyclodehydrations." Nature Chemical
Biology Nat Chem Biol 8.6 (2012): 569-75. Web.
5. Slabinski, Lukasz, Lukasz Jaroszewski, Ana P.C. Rodrigues, Leszek Rychlewski, Ian
A. Wilson, Scott A. Lesley, and Adam Godzik. "The Challenge of Protein Structure
Determination-lessons from Structural Genomics." Protein Science 16.11 (2007):
2472-482. Print.
6. Markley, Andrew, Emily Jensen, and Shaun Lee. "An Escherichia Coli-based
Bioengineering Strategy to Study Streptolysin S Biosynthesis." Analytical
Biochemistry 420 (2011): 191-93. Print.
7. Altschul, S., T. L. Madden, A. A. Schaffer, J. Zhang, W. Miller, and D. J. Lipman.
"Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search
Programs." Nucleic Acids Research 25.17 (1997): 3389-402. Web.
8. Fox, Jeffrey D., and David S. Waugh. "Maltose-Binding Protein as a Solubility
Enhancer." E. Coli Gene Expression Protocols 205 (2003): 99-118. Print.
9. Dong, Aiping, Xiaohui Xu, Aled M. Edwards, Changsoo Chang, Maksymilian
Chruszcz, Marianne Cuff, Marcin Cymborowski, Rosa Di Leo, Olga Egorova, Elena
Evdokimova, Ekaterina Filippova, Jun Gu, Jennifer Guthrie, Alexandr Ignatchenko,
Andrzej Joachimiak, Natalie Klostermann, Youngchang Kim, Yuri Korniyenko,
Wladek Minor, Qiuni Que, Alexei Savchenko, Tatiana Skarina, Kemin Tan,
Alexander Yakunin, Adelinda Yee, Veronica Yim, Rongguang Zhang, Hong Zheng,
Masato Akutsu, Cheryl Arrowsmith, George V. Avvakumov, Alexey Bochkarev,
Lars-Göran Dahlgren, Sirano Dhe-Paganon, Slav Dimov, Ludmila Dombrovski,
Patrick Finerty, Susanne Flodin, Alex Flores, Susanne Gräslund, Martin
Hammerström, Maria Dolores Herman, Bum-Soo Hong, Raymond Hui, Ida
Johansson, Yongson Liu, Martina Nilsson, Lyudmila Nedyalkova, Pär Nordlund,
Tomas Nyman, Jinrong Min, Hui Ouyang, Hee-won Park, Chao Qi, Wael Rabeh,
Limin Shen, Yang Shen, Deepthi Sukumard, Wolfram Tempel, Yufeng Tong, Lionel
Tresagues, Masoud Vedadi, John R. Walker, Johan Weigelt, Martin Welin, Hong Wu,
Ting Xiao, Hong Zeng, and Haizhong Zhu. "In Situ Proteolysis for Protein
Crystallization and Structure Determination." Nature Methods 4.12 (2007): 1019-021.
Print.

158

10. Fersht, A. "The Folding of an Enzyme I. Theory of Protein Engineering Analysis of
Stability and Pathway of Protein Folding." Journal of Molecular Biology 224.3
(1992): 771-82. Print.
11. Walter, Thomas S., Christoph Meier, Rene Assenberg, Kin-Fai Au, Jingshan Ren,
Anil Verma, Joanne E. Nettleship, Raymond J. Owens, David I. Stuart, and Jonathan
M. Grimes. "Lysine Methylation as a Routine Rescue Strategy for Protein
Crystallization." Structure 14.11 (2006): 1617-622. Print.
12. Lund, A. H., M. Duch, and F. Skou Pedersen. "Increased Cloning Efficiency by
Temperature-Cycle Ligation." Nucleic Acids Research 24.4 (1996): 800-01. Print.
13. Lilie, Hauke, Elisabeth Schwarz, and Rainer Rudolph. "Advances in Refolding of
Proteins Produced in E. Coli." Current Opinion in Biotechnology 9.5 (1998): 497501. Web.
14. Thermo, Scientific. Pierce® Protein Refolding Kit. Protein Refolding Protocol. N.p.:
n.p., n.d. Pierce® Protein Refolding Kit. Thermo Scientific, 9 Feb. 2014. Web. 16
Mar. 2016.
15. Tolia, Niraj H., and Leemor Joshua-Tor. "Strategies for Protein Coexpression in
Escherichia Coli." Nature Methods Nat Meth 3.1 (2006): 55-64. Web.
16. Die, I. M. Van, H. E. N. Bergmans, and W. P. M. Hoekstra. "Transformation In
Escherichia Coli: Studies On The Role Of The Heat Shock In Induction Of
Competence." Microbiology 129.3 (1983): 663-70. Web.
17. "Double Digest Finder." Double Digest Finder. New England Biolabs, n.d. Web. 18
Jan. 2016.
18. Sambrook, Joseph, E. F. Fritsch, and Tom Maniatis. Molecular Cloning: A
Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
Print.

159

APPENDIX A – DSF LIGAND SCREENING CONDITIONS
Table A.1. Hampton screen additives (DSF)
(*All solutions also contain 0.1 M Tris (pH 7.5)*)
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
B1
B2
B3
B4
B5
B6
B7
B8
B9
B10
B11
B12
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
D1
D2

0.1M Barium Chloride
0.1M Cadmium Chloride
0.1M Calcium Chloride
0.1M Cobalt(II) Chloride
0.1M Copper(II) Chloride
0.1M Magnesium Chloride
0.1M Manganese(II) Chloride
0.1M Strontium Chloride
0.1M Yttrium(III) Chloride
0.1M Zinc Chloride
0.1M Iron(III) Chloride
0.1M Nickel(II) Chloride
0.1M Chromium(III) Chloride
0.1M Praseodymium(III) Acetate
1M Ammonium Sulfate
1M Potassium Chloride
1M Lithium Chloride
2M Sodium Chloride
0.5M Sodium Fluoride
1M Sodium Iodide
2M Sodium Thiocyanate
1M Potassium Sodium Tartrate
1M Sodium Citrate
1M Cesium Chloride
1M Sodium Malonate
0.1M L-Proline
0.1M Phenol
30% DMSO
0.1M Sodium Bromide
30% 6-aminohexanoic acid
30% 1,5-diaminopentane
30% 1,6-diaminohexane
30% 1,8-diaminooctane
1M Glycine
0.3M Glycyl-glycyl-glycine
0.1M Taurine
0.1M Betaine HCl
0.1M Spermidine

D3
D4
D5
D6
D7
D8
D9
D10
D11

0.1M Spermidine x 4HCl
0.1M Hexammine Cobalt(III) Chloride
0.1M Sarcosine
0.1M Trimethylamine HCl
1M Guanidine HCl
0.1M Urea
0.1M β-Nicotinamide Adenine
0.1M ATP
0.1M TCEP HCl

D12
E1
E2
E3
E4
E5
E6
E7
E8
E9
E10
E11
E12
F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12
G1
G2
G3
G4
G5
G6
G7
G8
G9
G10
G11
G12
H1
H2
H3
H4
H5
H6
H7
H8
H9
H10
H11
H12

160

0.01M GSH
0.1M EDTA
5% Polyvinylpyrrolidone
30% Dextran Sulfate Sodium Chloride
40% Pentaerythritol ethoxylate
10% PEG 3350
30% D-(+)-Glucose
30% Sucrose
30% Xylitol
30% D-Sorbitol
12% Myo-inositol
30% D-(+)-Trehalose
30% D-(+)-Galactose
30% Ethylene Glycol
30% Glycerol
3M NDSB-195
2M NDSB-201
2M NDSB-211
2M NDSB-221
1M NDSB-256
0.15mM CYMAL-7
20% Benzamidine
5% LDAO, DDAO
5% n-octyl-β-D-glucoside
5% n-dodecyl-β-D-maltoside
30% Trimethylmine-N-oxide
30% 1,6-hexanediol
30% 2-methyl-2,4-pentanediol
50% PEG 400
40% Jeffamine M-600
40% 2,5-hexanediol
40% 1,3-butanediol
40% PEG 400
30% 1,4-dioxane
30% Ethanol
30% 2-Propanol
30% Methanol
40% 1,4-butanediol
40% tert-butanol
40% 1,3-propanediol
40% Acetonitrile
40% Formamide
40% 1-propanol
5% Ethylacetate
40% Acetone
0.25% Dichloromethane
7% 1-butanol
40% 2,2,2-trifluoroethanol
40% 1,1,1,3,3,3-hexafluoro-2-propano

Table A.2: DSF ligand screen 2
(*All solutions also contain 0.05 M Tris (pH 7.5)*)
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
B1
B2
B3
B4
B5
B6
B7
B8
B9
B10
B11
B12
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
ester
D1

0.1M Valine
0.1M Alanine
0.1M Arginine
0.1M Malate
0.1M Sodium Citrate
0.1M Threonine
0.1M Glutamine
0.1M Isoleucine
0.1M Succinate
0.1M Sodium Pyruvate
0.1M Glucose
0.1M Lysine
0.1M Asparagine
0.1M Homoserine
0.1M Cytosine
0.1M Glutamate
0.1M Proline
0.1M Taurine
0.1M Nicotinamide
0.1M Guanine
0.1M Glycine
0.1M Serine
0.1M Methionine
0.1M 4-methylcatechol
0.1M Citrate
0.1M Nicotinamide
0.01M Magnesium Chloride
0.1M Leucine
0.01M Zinc Chloride
0.01M Iron(III) Chloride
0.1M Sodium Pyrophosphate
0.1M Thymine
0.1M Sucrose
0.01M Calcium Chloride
0.1M Spermidine
0.1M 2,6-Pyridine dicarboxylic acid methyl

D2
D3
D4
D5
ester
D6
D7
D8
D9
D10

0.1M Sodium Cholate
0.1M Sodium Pyrophosphate
0.01M Manganese(II) Chloride
0.1M 2,6-Pyridine dicarboxylic acid ethyl

D11
0.1M Phenylalanine
D12
0.1M Uracil
E1
0.1M Mercaptosuccinate
E2
0.1M γ-amino-butyric acid
E3
0.1M 8-hydroxy-2-quinole carboxylic acid
E4
0.1M Pimelic acid
E5
0.1M Sodium Benzene 1,3-disulfonate
E6
0.1M 6-oxo-pipecolinic acid
E7
0.1M Kanamycin
E8
0.1M 5-amino-isophthalic acid
E9
0.1M Chelidanic acid
E10
0.1M 2-pyridine sulfonic acid
E11
0.1M 2-proline
E12
0.1M Gly-gly
F1
0.1M 3,3',5,5'-tetracarboxyl
diphenalmethane
F2
0.1M 5-nitrofuroic acid
F3
0.1M 4,5-dibromo-2-furoic acid
F4
0.1M 5-sulfoisophthalic acid
F5
0.1M Betaine
F6
0.1M isocitric acid lactone
F7
0.1M 3-aminobenzene sulfonic acid
F8
0.1M Chelidonic acid
F9
0.1M 1,3,5-benzene tricarboxylic acid
F10
0.1M isocitric acid
F11
0.1M p-coumaric acid
F12
0.1M 2,5-thiophene dicarboxylic acid
G1
0.1M Phosphoserine
G2
0.1M Tartaric acid
G3
0.1M Arabinose
G4
0.1M Chloramphenicol
G5
0.1M Naringin
G6
0.1M Caffeic acid
G7
0.1M 2,4-pyridine dicarboxylic acid
G8
0.1M 2,3-pyridine dicarboxylic acid
G9
0.1M 3,5-pyridine dicarboxylic acid
G10
0.1M 2,5-pyridine dicarboxylic acid
G11
0.1M Tyrosine
G12
0.1M Rutin
H1
0.1M Morin
H2
0.01M Copper(II) Chloride
H3
0.1M Maltose
H4
0.1M AMP
H5
0.1M Myo-inositol
H6
0.1M Ascorbic acid
H7
0.1M Thiamine
H8
0.1M Pimelic acid
H9
0.1M 3-aminobenzene sulfonic acid
H10
0.1M Melamine
H11
0.1M 2,5 FDC
H12
0.1M Cystine

0.1M Tryptophan

0.1M Aspartate
0.1M Adenine
0.1M Xylitol
0.01M Cobalt(II) Chloride
0.1M 2,6-Pyridine dicarboxylic acid
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Table A.3: DSF ligand screen 3
(*All solutions also contain 0.1 M Tris (pH 7.5)*)
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
B1
B2
B3
B4
B5
B6
B7
B8
B9
B10
B11
B12
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
D1
D2
D3
D4
D5
D6
D7
D8
D9
D10
D11
D12
E1
E2
E3
E4
E5
E6
E7
E8
E9
E10

30% Methanol
30% Ethanol
30% DMSO
40% Acetone
30% Glycerol
30% Ethylene Glycol
0.1M Bromosuccinic acid
0.1M Cytidine
0.1M Cytidine in 100% Ethanol
0.1M Sodium Deoxycholate
0.1M Sodium Chloride
0.1M Trimesic acid
0.1M Histidine HCl
0.1M 1,4-butanediol
0.1M Neopentyl Alcohol
0.1M Cadmium Chloride
0.1M Malonic acid
0.1M 3,4-dihydroxybenzoic acid
0.1M CHES
0.1M MOPS
0.1M L-norvaline
0.1M 1,6-hexanediol
0.1M Lanthanum Chloride Heptahydrate
0.1M Vanillin
0.1M Kanamycin Sulfate
0.1M N,N-dimethylglycine
0.1M Salicylic acid
0.1M 3-hydroxy-2-naphthoic acid
0.1M Tris(hydroxymethyl)aminomethane
0.1M CAPS
0.1M Ethylene Glycol
0.1M Chloroquine
0.1M Potassium Thiocyanate
0.1M Fast Garnet GBC Salt
0.1M N,N-dimethyldecylamine-N-oxide
0.1M 1,4-butanediphosphonic acid
0.1M Lithium Acetate
0.1M Magnesium Nitrate
0.1M Fast Violet B Salt
0.1M β-NAD
0.1M α-lactose monohydrate
0.1M Guanidine Thiocyanate
0.1M Sodium Bisulfate
0.1M BOC-L-serine
0.1M Glutathione (reduced)
0.1M PIPES
0.1M Sodium Bicarbonate
0.1M Thiourea
0.1M α-naphthyl acid phosphate
0.1M Streptomycin Sulfate
0.1M Hexamine Cobalt(III) Chloride
0.1M Magnesium Sulfate
0.1M Lithium Sulfate
0.1M 4-dimethylaminopyridine
0.1M S-(-)-2-bromopropionic acid
0.1M O-phospho-DL-serine
0.1M Nickelous Acetate
0.1M Tetraamine Copper(II) Sulfate

E11
0.1M Potassium Tetrachloroplatinate
E12
0.1M Ammonium Cerium(IV) Nitrate
F1
0.1M Chromium Acetate
F2
0.1M Trifluoroacetic acid Silver Salt
F3
0.1M Nicotinic acid
F4
0.1M Trimethyl Lead Acetate
F5
0.1M Propylenediphosphonic acid
F6
0.1M Nickel Sulfate
F7
0.1M Tetraethylpropylene-1,3-diphosphonic
acid
F8
0.1M 1,6-hexane bis-phosphonic acid
F9
0.1M Cesium Fluoride
F10
0.1M Strontium Nitrate
F11
0.1M Cobaltous Sulfate
F12
0.1M Glutathione
G1
0.1M Cerous Chloride
G2
0.1M Sodium Molybdate(III) dehydrate
G3
0.1M Thallium(I) Nitrate
G4
0.1M Cesium Chloride
G5
0.1M Iodoacetamide
G6
0.1M Phosphonoacetic acid
G7
0.1M 2,6-naphthalenedisulfonic acid
disodium salt
G8
0.1M Propionic acid
G9
0.1M Calcium Acetate
G10
0.1M 1,1,3,3-tetramethylurea
G11
0.1M Adonitol
G12
0.1M Nicotinamide
H1
0.1M GMP
H2
0.1M Cacodylic acid
H3
0.1M Calcium Formate
H4
0.1M Lithium Citrate
H5
0.1M Imidazole
H6
0.1M Lithium Chloride
H7
30% Dextrose
H8
0.1M Sodium Sulfate
H9
0.1M Thymidine
H10
0.1M Potassium Hydrogen Phthalate
H11
0.1M Ferrous Sulfate
H12
0.1M Hydroxylaminohydrochloride
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Table A.4: DSF ligand screen 4
(*All solutions also contain 0.1 M Tris (pH 7.5)*)
A1
0.1M ADA (N-2-acetamide-2-iminodiacetic
acid)
A2
0.1M trans-4,5-dihydroxy-1,2-dithiane
A3
0.1M 1-naphthalene acetic acid
A4
0.1M β-alanine
A5
0.1M Potassium Chloride
A6
0.1M Cerium(III) Chloride Heptahydrate
A7
0.1M Lithium Fluoride
A8
0.1M 5,5'-dithiobis(2-nitrobenzoic acid)
A9
0.1M 1,2,4,5-benzenetetracarboxylic acid
A10
0.1M Cyclohexylsuccinic acid
A11
0.1M 6-(methoxycarbonyl) picolinic acid
A12
0.1M CHAPS
B1
0.1M trans-cinnamic acid
B2
0.1M Sulfonic acid
B3
0.1M Sodium 3-sulfobenzoate
B4
0.1M 8-anilino-1-naphthalene sulfonic acid
B5
0.1M N-bromosuccinimide
B6
0.1M Terephthalic acid
B7
0.1M Chlorosuccinic acid
B8
0.1M Guanidine HCl
B9
2% Triton-X114
B10
0.1M L-serine
B11
0.1M Dextrose Anhydrous
B12
0.1M Sodium Tartrate Dihydrate
C1
0.1M Sodium Acetate Trihydrate
C2
0.1M PEG 400
C3
10% Poly(vinyl Alcohol)
C4
0.1M 1,2-dihydroxybenzene
C5
0.1M Sodium Malonate Dibasic
Monohydrate
C6
0.1M 5-aminovaleric acid

E3
0.1M Potassium Sulfate
E4
0.1M Sodium Carbonate
E5
0.06M N-bromosuccinic acid in 40%
Acetone
E6
0.07M Thymol in 30% Ethanol
E7
0.07M 2-adamantanone in 30% Methanol
E8
0.07M N-bromosuccinic acid in 30% DMSO
E9
0.01M 2,2'-azino-bis(3ethylbenzothiazoline-6-sulfonic acid)
E10
0.07M Sodium Tetraborate in 30% Ethylene
Glycol
E11
0.1M Mellitic acid
E12
0.1M methyl-6-hydroxymethyl-2carboxylate pyridine
F1
0.07M Decanoic acid in 30% Ethanol
F2
0.01M Tetrasodium Pyrophosphate
F3
0.07M Thymine in 30% Methanol
F4
0.01M Calcium Gluconate
F5
0.01M D-2-phosphoglyceric acid
F6
0.07M Hexadecyltrimethylammonium
bromide in 30% Ethanol
F7
0.07M 1,3-dicyclohexyl-carbodiimide in
30% Ethanol
F8
0.01M Asparagine
F9
0.01M Calcium Sulfate
F10
0.07M 2,4-dibromophenol in 30% Ethanol
F11
0.01M Adenine
F12
0.07M 3-amino-4-hydroxybenzoic acid in
30% Ethanol
G1
0.06M 3-amino-4-hydroxybenzoic acid in
40% Acetone
G2
0.01M Phenylurea
G3
0.06M Chloramphenicol in 40% Acetone
G4
0.07M Thymine in 30% DMSO
G5
0.06M 3-indoleacetic acid in 40% Acetone
G6
0.07M Melamine in 30% Glycerol
G7
0.07M 5-iodosalicylic acid in 30% Ethanol
G8
0.07M 4-aminobiphenyl in 30% DMSO
G9
0.01M Magnesium Citrate
G10
0.07M Caffeine in 30% Ethanol
G11
0.07M Quinine HCl in 30% Ethanol
G12
0.07M Rhodanine in 30% Ethanol
H1
0.1M (2R,6S)-2,6-piperdinedicarboxylate
H2
0.1M 8-aminooctanoic acid
H3
0.1M O-phospho-L-serine
H4
0.1M Diphenylamino-4-sulfonic acid
H5
0.1M Phytic acid
H6
0.1M TCEP HCl
H7
0.01M Samarium Sulfate
H8
0.01M Dibutylthiourea
H9
0.07M 2,6-dibromophenol in 30% Ethanol
H10
0.07M Kinetin in 30% DMSO
H11
0.07M 1-phenyl-2-thiourea in 30% Ethanol
H12
0.01M Thallium Chloride

C7
0.05M PEG 8000
C8
0.1M PEG 200
C9
0.1M NDSB-221
C10
0.1M NDSB-201
C11
0.1M 2,2-dimethylsuccinic acid
C12
0.05M PEG 6000
D1
0.1M PEG 4000
D2
0.1M NDSB-256
D3
0.1M Glycerol
D4
0.1M MES Free Acid Monohydrate
D5
0.1M PEG 2000 MME
D6
0.1M PEG 5000 MME
D7
0.1M NDSB-195
D8
0.1M Phthalic acid
D9
0.1M 2-methyl-2,4-pentanediol
D10
0.1M PEG 3350
D11
0.1M PEG 1000
D12
0.1M 2-hydroxy-2-(2-isopropoxy-2oxoethyl) succinic acid
E1
0.1M 6-(ethoxylcarbonyl) Picolinic acid
E2
0.1M EDTA
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